Collected Works of Michael Hallek

Dr. Michael Hallek is the founder of the German CLL Study Group and was instrumental in the formation of the European Research Initiative on CLL (ERIC). Dr. Hallek received his medical degree from the Ludwig Maximilian University of Munich and he was a research associate at the Dana-Farber Cancer Institute. Between 1994 and 2005, he was head of the Gene Therapy program at the Gene Center at the Ludwig Maximilian University of Munich and was head of the Clinical Cooperation Group for Gene Therapy at the GSF-National Research Center for Environment and Health in Munich. Since 2003, he has been a Professor of Internal Medicine, Director and Chair of the Department of Internal Medicine I at the University Hospital of Cologne, and he is the Director of the Center of Integrated Oncology (CIO) in Cologne. He has received several awards, including the Rai-Binet Medal in 2013. Dr. Hallek is currently an associate editor of Blood, the premier journal of the American Society of Hematology.

A set of video clips in which Dr. Hallek discusses the development of his research may be found in the Oral History archive.

Collected Works

1985

Hallek M, Seidler A. Medizinstudium in Frankreich: eine alternative zur ausbildung in Deutschland. Fortschr Med. 1985 Apr 25;103(16):88-9.

1987

Reinberg A, Hallek M, Levi F, Touitou Y, Smolensky M. Aspects of chronopharmacology and chronotherapy in pediatrics. Prog Clin Biol Res. 1987;227B:249-58.
Reinberg A, Smolensky M, Labrecque G, Hallek M. Aspects of chronopharmacology and chronotherapy in children. Chronobiologia. 1987 Jul-Sep;14(3):303-25.

1988

Reinberg A, Smolensky MH, Hallek M, Smith KD, Steinberger E. Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy. Fertil Steril. 1988 Feb;49(2):309-15.
Hallek M, Szinicz L. Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro. Biochem Pharmacol. 1988 Mar 1;37(5):819-25.
Reithmann C, Arbogast H, Hallek M, Auburger G, Szinicz L. Studies on the role of central catecholaminergic mechanisms in the antidotal effect of the oxime HI 6 in soman poisoned mice. Arch Toxicol. 1988 Aug;62(1):41-4.
Hallek M, Emmerich B, Strohmeyer S, Busch R, Reichle A, Senekowitsch R. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Klin Wochenschr. 1988 Aug 15;66(16):718-23.

1989

Hallek M, Lévi F, Haen E, Emmerich B. Bedeutung der chronopharmakologie für die onkologie. Onkologie. 1989 Oct;12(5):230-8.

1990

Emmerich B, Emslander HP, Milatovic D, Hallek M, Pachmann K. Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis. Lung. 1990;168 Suppl:726-31.
Emmerich B, Emslander HP, Pachmann K, Hallek M, Milatovic D, Busch R. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration. 1990;57(2):90-9.

1991

Liebl B, Pachmann K, Römer U, Haen E, Hallek M, Emmerich B. Quantitation of mRNA for the beta-adrenoceptor gene in human mononuclear leucocytes by in situ hybridization with fluorochrome labeled cloned DNA. J Recept Res. 1991;11(1-4):473-82.
Engelhard M, Meusers P, Brittinger G, Brack N, Dornoff W, Enne W, Gassmann W, Gerhartz H, Hallek M, Heise J, Hettchen W, Huhn D, Kabelitz K, Kuse R, Lengfelder E, Ludwig F, Meuthen I, Radtke H, Schadeck C, Schöber C, Schumacher E, Siegert W, Staiger HJ, Terhardt E, Thiel E, Thomas M, Wagner T, Willems MG, Wilmanns W, Zwingers T, Stein H, Tiemann M, Lennert K. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol. 1991 Feb;2 Suppl 2:177-80.
Hallek M, Kamp T, Haen E, Göhly U, Emmerich B, Remien J. Reduced responsiveness of adenylate cyclase to forskolin in human lymphoma cells. Biochem Pharmacol. 1991 Sep 12;42(7):1329-34.

1992

Melchart D, Martin P, Hallek M, Holzmann M, Jurcic X, Wagner H. Circadian variation of the phagocytic activity of polymorphonuclear leukocytes and of various other parameters in 13 healthy male adults. Chronobiol Int. 1992;9(1):35-45.
Okuda K, Sanghera JS, Pelech SL, Kanakura Y, Hallek M, Griffin JD, Druker BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood. 1992 Jun 1;79(11):2880-7.
Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul;65(1):1-5.
Hallek M, Druker B, Lepisto EM, Wood KW, Ernst TJ, Griffin JD. Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line. J Cell Physiol. 1992 Oct;153(1):176-86.
Hallek M, Lepisto EM, Slattery KE, Griffin JD, Ernst TJ. Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1992 Oct 1;80(7):1736-42.

1994

Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ, Griffin JD. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18;269(7):5016-21.
Hallek M, Ando K, Eder M, Slattery K, Ajchenbaum-Cymbalista F, Griffin JD. Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7. Leukemia. 1994 May;8(5):740-8.
Adler S, Lang S, Langenmayer I, Eibl-Eibesfeldt B, Rump W, Emmerich B, Hallek M. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. Cancer. 1994 Jun 15;73(12):2905-12.
Lévi F, Tampellini M, Metzger G, Bizi E, Lemaigre G, Hallek M. Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. Int J Cancer. 1994 Nov 15;59(4):543-7.

1995

Hallek M, Szinicz L. Methantheline improves the reactivation by HI 6 of human erythrocyte acetylcholinesterase inhibited by soman in vitro. Arch Toxicol. 1995;70(1):16-9.
Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Tantravahi R, Chen LB, Griffin JD. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995 Mar 10;270(10):5039-47.
Wendtner CM, Schmitt B, Gruss HJ, Druker BJ, Emmerich B, Goodwin RG, Hallek M. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin’s lymphoma cell line. Cancer Res. 1995 Sep 15;55(18):4157-61.
Pignata C, Prasad KV, Hallek M, Druker B, Rudd CE, Robertson MJ, Ritz J. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995 Oct 15;165(2):211-6.
Chiorini JA, Wendtner CM, Urcelay E, Safer B, Hallek M, Kotin RM. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther. 1995 Dec;6(12):1531-41.

1996

Neumann C, Zehentmaier G, Danhauser-Riedl S, Emmerich B, Hallek M. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol. 1996 Feb;26(2):379-84.
Hallek M, Wendtner CM. Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: recent advances and potential clinical applications. Cytokines Mol Ther. 1996 Jun;2(2):69-79.
Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B, Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996 Jul;94(1):5-16.
Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek I, Emmerich B. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996 Aug;22(5-6):439-47.
Langenmayer I, Nerl C, Knauf W, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HW, Thiel E, Emmerich B. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br J Haematol. 1996 Aug;94(2):362-9.
Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996 Aug 1;56(15):3589-96.
Montserrat E, Hallek M. Current strategies for the treatment of CLL. Leuk Lymphoma. 1996 Oct;22(Suppl 2):65-8.

1997

Kamp T, Liebl B, Haen E, Emmerich B, Hallek M. Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest. 1997 Feb;27(2):121-7.
Hallek M, Kuhn-Hallek I, Emmerich B. Prognostic factors in chronic lymphocytic leukemia. Leukemia. 1997 Apr;11 Suppl 2:S4-13.
Knauf WU, Ehlers B, Mohr B, Thiel E, Langenmayer I, Hallek M, Emmerich B, Adorf D, Nerl C, Zwingers T. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood. 1997 Jun 1;89(11):4241-2.
Wendtner CM, Nolte A, Mangold E, Buhmann R, Maass G, Chiorini JA, Winnacker EL, Emmerich B, Kotin RM, Hallek M. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 1997 Jul;4(7):726-35.
Doenecke A, Winnacker EL, Hallek M. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia. 1997 Oct;11(10):1787-92.
Knauf WU, Langenmayer I, Ehlers B, Mohr B, Adorf D, Nerl CH, Hallek M, Zwingers TH, Emmerich B, Thiel E. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1997 Nov;27(5-6):523-32.
Hallek M, Touitou Y, Lévi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R, Emmerich B. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Clin Chim Acta. 1997 Nov 28;267(2):155-66.
Hallek M, Neumann C, Schäffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1997 Dec;25(13):1367-77.
Warmuth M, Bergmann M, Priess A, Häuslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem. 1997 Dec 26;272(52):33260-70.

1998

Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998 Jan 1;91(1):3-21.
Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin’s lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998 May;21(9):909-16.
Maass G, Bogedain C, Scheer U, Michl D, Hörer M, Braun-Falco M, Volkenandt M, Schadendorf D, Wendtner CM, Winnacker EL, Kotin RM, Hallek M. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther. 1998 May 1;9(7):1049-59.
Braun-Falco M, Hallek M. Hautgentherapie – perspektiven des gentransfers in keratinozyten. Hautarzt. 1998 Jul;49(7):536-44.
Hallek M, Girod A, Braun-Falco M, Wendtner CM, Bogedain C, Hörer M. Recombinant adeno-associated virus vectors. IDrugs. 1998 Sep;1(5):561-73.

1999

Hallek M, Emmerich B, Nowrousian MR. Individual risk assessment for patients with haematological malignancies: a basis for optimized treatment strategies. Stuttgart, Germany: Georg Thieme Verlag; 1999.
Hallek M, Kuhn-Hallek J, Emmerich B. Prognostic factors in chronic lymphocytic leukaemia. In Hallek M, Emmerich B, Nowrousian MR. Individual risk assessment for patients with haematological malignancies: a basis for optimized treatment strategies. Stuttgart, Germany: Georg Thieme Verlag; 1999.
Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med (Berl). 1999 Feb;77(2):282-93.
Warmuth M, Danhauser-Riedl S, Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol. 1999 Feb;78(2):49-64.
Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther. 1999 Mar;6(3):432-41.
Wendtner CM, Buhmann R, Kolb HJ, Emmerich B, Hallek M. Rezidivierender schwindel und synkopen bei einer patientin mit eosinophilie. Internist (Berl). 1999 Mar;40(3):305-10.
Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, Emmerich B. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999 Mar 1;93(5):1732-7.
Krämer A, Hörner S, Willer A, Fruehauf S, Hochhaus A, Hallek M, Hehlmann R. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2087-92.
Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999 Mar 15;93(6):1992-2002.
Selmayr M, Strehl J, Kremer JP, Kremmer E, Doenecke A, Hallek M, Menzel H, Thielemans K, Thierfelder S, Mocikat R. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther. 1999 May;6(5):778-84.
Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M. Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy. Ann Oncol. 1999 May;10(5):505-9.
Schmitter D, Bolliger U, Hallek M, Pichert G. Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells. Br J Haematol. 1999 Jul;106(1):64-70.
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. 1999 Sep;5(9):1052-6.
Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K. Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol. 1999 Oct;78(10):475-7.
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. Errata. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. 1999 Dec;5(12):1438.

2000

Nolte A, Buhmann R, Emmerich B, Schendel D, Hallek M. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin’s lymphoma. Br J Haematol. 2000 Feb;108(2):415-23.
von Bubnoff N, Adler S, Danhauser-Riedl S, Kamp T, Nerl C, Emmerich B, Hallek M. The activation of intracellular tyrosine kinases by interferon-alpha (IFNα) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukemia patients. Ann Hematol. 2000 Mar;79(3):119-26.
Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res. 2000 May;6(5):1958-68.
Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000 Sep;79(9):493-500.
Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000 Sep 1;96(5):1933-9.
Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol. 2000 Oct;74(19):9281-93.

2001

Wendtner CM, Schmitt B, Bergmann M, Röhnisch T, Buhmann R, Hallek M. New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. Int J Hematol. 2001 Jan;73(1):32-8.
Braun-Falco M, Hallek M. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch Dermatol Res. 2001 Feb;293(1-2):12-7.
Hacker UT, Gerner FM, Büning H, Hutter M, Reichenspurner H, Stangl M, Hallek M. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors. Gene Ther. 2001 Jun;8(12):966-8.
Hallek M, Schmitt B, Emmerich B, Stein H. Chronische lymphatische Leukämie – Teil 1: Diagnostik. Dtsch Med Wochenschr. 2001 Jun 8;126(23):687-9.
Hallek M, Schmitt B, Emmerich B, Stein H. Chronische lymphatische Leukämie – Teil 2: Therapie. Dtsch Med Wochenschr. 2001 Jun 8;126(23):690-5.
Schmitt B, Hallek M. Chronische lymphatische Leukämie – Teil 3: Der konkrete fall. Dtsch Med Wochenschr. 2001 Jun 8;126(23):695.
Hallek M, Schmitt B, Wilhelm M, Busch R, Kröber A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Döhner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001 Aug;114(2):342-8.
Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther. 2001 Sep;4(3):174-81.
Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001 Sep 1;98(5):1326-31.
Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK, Wilhelm M. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood. 2001 Sep 15;98(6):1991-2.
Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM. Grundlagen der gentherapie prinzipien und stand der entwicklung. Internist (Berl). 2001 Oct;42(10):1306-8, 1311-3.
Seisenberger G, Ried MU, Endress T, Büning H, Hallek M, Bräuchle C. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science. 2001 Nov 30;294(5548):1929-32.
Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G, Hallek M. Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol Cell Biol. 2001 Dec;21(23):8068-81.

2002

Hallek M, Bergmann M, Wendtner CM, Fingerle-Rowson G, Schmitt B. Allogeneic stem cell transplantation in chronic lymphocytic leukemia: the con’s. Ann Hematol. 2002;81 Suppl 2:S48-50.
Keating M, Hallek M. Guest editorial. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52. Med Oncol. 2002;19 Suppl:S1-2.
Rai K, Hallek M. Future prospects for alemtuzumab (MabCampath). Med Oncol. 2002;19 Suppl:S57-63.
Hallek M. Fludarabin als primäres therapeutikum bei chronischer lymphatischer leukämie. Internist (Berl). 2002 Apr;43(4):563-4, 565-6.
Hallek M. Welche Auswirkungen hat das Vorkommen von Prolymphozyten auf die Prognose und die Therapie der CLL? Dtsch Med Wochenschr. 2002 Mar 1;127(9):464.
Bräuchle C, Seisenberger G, Endress T, Ried MU, Büning H, Hallek M. Single virus tracing: visualization of the infection pathway of a virus into a living cell. Chemphyschem. 2002 Mar 12;3(3):299-303.
Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002 May;83(Pt 5):973-8.
Ried MU, Girod A, Leike K, Büning H, Hallek M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol. 2002 May;76(9):4559-66.
Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma. 2002 Jun;3(1):26-35.
Nagy ZA, Hubner B, Löhning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, Zahn S, Leyer S, Schier EM, Zahradnik A, Brunner C, Lobenwein K, Rattel B, Stanglmaier M, Hallek M, Wing M, Anderson S, Dunn M, Kretzschmar T, Tesar M. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002 Aug;8(8):801-7. Epub 2002 Jul 8.
Buhmann R, Kurzeder C, Rehklau J, Westhaus D, Bursch S, Hiddemann W, Haferlach T, Hallek M, Schoch C. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol. 2002 Sep;118(4):968-75.
Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C, Perabo L, Danhauser-Riedl S, Baumert J, Hiddemann W, Hallek M, Büning H. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2002 Sep 1;100(5):1655-61.
Hallek M, Bergmann M, Brittinger G, Döhner H, Dreger P, Herold M, Hopfinger G, Jäger U, Knauf W, Nerl C, Rummel M, Schmitt B, Wendtner CM, Emmerich B. Chronische lymphatische leukämie aktuelle therapiekonzepte. Internist (Berl). 2002 Oct;43(10):1245-54.
Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002 Nov 1;100(9):3115-20.

2003

Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M, Warmuth M. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood. 2003 Jan 15;101(2):655-63. Epub 2002 Sep 12.
Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 2003 Jan 15;101(2):664-72. Epub 2002 Sep 5.
Huttner NA, Girod A, Schnittger S, Schoch C, Hallek M, Büning H. Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid. J Gene Med. 2003 Feb;5(2):120-9.
Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia. 2003 Feb;17(2):283-9.
Wendtner CM, Kurzeder C, Theiss HD, Kofler DM, Baumert J, Delecluse HJ, Janz A, Hammerschmidt W, Hallek M. High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors. Exp Hematol. 2003 Feb;31(2):99-108.
Büning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M. Receptor targeting of adeno-associated virus vectors. Gene Ther. 2003 Jul;10(14):1142-51.
Perabo L, Büning H, Kofler DM, Ried MU, Girod A, Wendtner CM, Enssle J, Hallek M. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther. 2003 Jul;8(1):151-7.
Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B. Aktuelle Konzepte bei chronischer lymphatischer Leukämie. Bessere Chancen für junge Patienten. MMW Fortschr Med. 2003 Jul 10;145(27-28):46-9.
Büning H, Nicklin SA, Perabo L, Hallek M, Baker AH. AAV-based gene transfer. Curr Opin Mol Ther. 2003 Aug;5(4):367-75.
Wahl U, Nössner E, Kronenberger K, Gangnus R, Pohla H, Staege MS, Kolb HJ, Hallek M, Mocikat R. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. Clin Cancer Res. 2003 Sep 15;9(11):4240-6. https://clincancerres.aacrjournals.org/content/9/11/4240.long
Nicklin SA, Dishart KL, Buening H, Reynolds PN, Hallek M, Nemerow GR, Von Seggern DJ, Baker AH. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 2003 Nov 25;201(2):165-73.
Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 2003 Dec;10(26):2139-47.
Theiss HD, Kofler DM, Büning H, Aldenhoff AL, Kaess B, Decker T, Baumert J, Hallek M, Wendtner CM. Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides. Exp Hematol. 2003 Dec;31(12):1223-9.

2004

Büning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs. 2004;177(3):139-50.
Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J. 2004;5(Suppl 1):S20-30.
Hallek M, Bergmann M, Emmerich B. Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment. Onkologie. 2004 Feb;27(1):97-104.
Work LM, Nicklin SA, Brain NJ, Dishart KL, Von Seggern DJ, Hallek M, Büning H, Baker AH. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther. 2004 Feb;9(2):198-208.
White SJ, Nicklin SA, Büning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004 Feb 3;109(4):513-9. Epub 2004 Jan 19.
Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbuget N, Hoelzer D, Uberla K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T, Hasford J. The German competence network ‘Acute and chronic leukemias’. Leukemia. 2004 Apr;18(4):665-9.
Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004 May;36(5):453-61. Epub 2004 Apr 18.
Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma. 2004 May;45(5):897-904.
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 Jun;18(6):1093-101.
Krych M, Dreyling M, Kneba M, Hoelzer D, Hiddemann W, Hallek M. Prophylaxe und differenzielle therapie des tumorlysesyndroms. Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1440-5.
Wendtner CM, Eichhorst BF, Hallek MJ. Advances in chemotherapy for chronic lymphocytic leukemia. Semin Hematol. 2004 Jul;41(3):224-33.
Kofler DM, Büning H, Mayr C, Bund D, Baumert J, Hallek M, Wendtner CM. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004 Sep;11(18):1416-24.
Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol. 2004 Oct;83(10):634-45. Epub 2004 Aug 7.

2005

Hallek M; German CLL Study Group. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematology Am Soc Hematol Educ Program. 2005:285-91.
Hallek M, Stahel RA, Greil R; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. Ann Oncol. 2005;16(Suppl 1):i50-1.
Koppold B, Sauer G, Büning H, Hallek M, Kreienberg R, Deissler H, Kurzeder C. Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. Int J Oncol. 2005 Jan;26(1):95-101.
Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood. 2005 Feb 15;105(4):1566-73. Epub 2004 Oct 7.
Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005 Mar;90(3):391-9.
Schmid C, Diem H, Herrmann K, Voltz R, Ott G, Hallek M. Unusual sites of malignancies: CASE 2. Central neurogenic hyperventilation as a complication of Richter’s syndrome. J Clin Oncol. 2005 Mar 20;23(9):2096-8.
Hallek M. Chemoimmunotherapy–towards real progress in the treatment of chronic lymphocytic leukemia. Nat Clin Pract Oncol. 2005 Jul;2(7):338-9.
Hallek M. Interleukin-6-mediated cell growth in multiple myeloma–a role for Viscum album extracts? Onkologie. 2005 Aug;28(8-9):387. Epub 2005 Aug 29.
Lux K, Goerlitz N, Schlemminger S, Perabo L, Goldnau D, Endell J, Leike K, Kofler DM, Finke S, Hallek M, Büning H. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol. 2005 Sep;79(18):11776-87.
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005 Sep 15;106(6):2018-25. Epub 2005 May 24.
Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005 Oct;90(10):1357-64.
Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.
Hacker UT, Wingenfeld L, Kofler DM, Schuhmann NK, Lutz S, Herold T, King SB, Gerner FM, Perabo L, Rabinowitz J, McCarty DM, Samulski RJ, Hallek M, Büning H. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med. 2005 Nov;7(11):1429-38.
Mayr C, Kofler DM, Büning H, Bund D, Hallek M, Wendtner CM. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood. 2005 Nov 1;106(9):3223-6. Epub 2005 Jul 12.

2006

Lehnhardt FG, Scheid C, Holtik U, Burghaus L, Neveling M, Impekoven P, Rüger A, Hallek M, Jacobs AH, Rubbert A. Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus. 2006;15(4):240-3.
Hellebrand E, Mautner J, Reisbach G, Nimmerjahn F, Hallek M, Mocikat R, Hammerschmidt W. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther. 2006 Jan;13(2):150-62.
Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner CM. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol. 2006 Jan;34(1):44-53.
Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006 Jan 15;107(2):742-51. Epub 2005 Sep 22.
Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M, Büning H. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med. 2006 Feb;8(2):155-62.
Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.
von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M, Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006 Mar 1;107(5):1955-62. Epub 2005 Oct 6.
Work LM, Büning H, Hunt E, Nicklin SA, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M, Baker AH. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther. 2006 Apr;13(4):683-93. Epub 2006 Jan 4.
Hacker UT, Schildhauer I, Barroso MC, Kofler DM, Gerner FM, Mysliwietz J, Buening H, Hallek M, King SB. Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity. Cancer Immunol Immunother. 2006 May;55(5):547-57. Epub 2005 Jul 26.
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Exp Hematol. 2006 Jul;34(7):860-9.
Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S, Work LM, Janicki H, Hallek M, Baker AH, Büning H. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol. 2006 Jul;80(14):7265-9.
Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother. 2006 Aug;7(12):1641-51.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006 Aug 1;108(3):1092-9. Epub 2006 Mar 21.
Zenz T, Ritgen M, Dreger P, Kröber A, Barth TF, Schlenk R, Böttcher S, Hallek MJ, Kneba M, Bunjes D, Döhner H, Stilgenbauer S. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006 Sep 15;108(6):2127-30. Epub 2006 May 25.
Saussele S, Adam K, Hochhaus A, Béné MC, Büchner T, Burnett A, Finazzi G, Fonatsch C, Gluckman E, Gökbuget N, Grimwade DJ, Haferlach T, Hallek M, Hasford J, Hoelzer D, Ljungman P, Niederwieser D, Serve H, Simonsson B, de Witte TJ, Hehlmann R; European LeukemiaNet. Klinische Forschung im „European LeukemiaNet”. Dtsch Med Wochenschr. 2006 Oct 27;131(43):2423-6.
Koppold B, Sauer G, Buening H, Hallek M, Kreienberg R, Deissler H, Kurzeder C. Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol. 2006 Dec;132(12):787-94. Epub 2006 Jun 23.

2007

Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007 Jan;21(1):12-7. Epub 2006 Nov 16.
Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan;136(1):63-72. Epub 2006 Nov 3.
Allgeier T, Garhammer S, Nössner E, Wahl U, Kronenberger K, Dreyling M, Hallek M, Mocikat R. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Cancer Lett. 2007 Jan 8;245(1-2):275-83. Epub 2006 Mar 3.
Burdorf L, Schuhmann N, Postrach J, Thein E, Hallek M, Reichart B, Büning H, Schmoeckel M. AAV-mediated gene transfer to cardiac cells in a heterotopic rat heart transplantation model. Transplant Proc. 2007 Mar;39(2):567-8.
Owczarczyk K, Hilker R, Brunn A, Hallek M, Rubbert A. Progressive multifocal leucoencephalopathy in a patient with sarcoidosis–successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford). 2007 May;46(5):888-90. Epub 2007 Mar 27.
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May;21(5):956-64. Epub 2007 Mar 15.
Hallek M, ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007 Apr;18 Suppl 2:ii49-50.
Re D, Elter T, Hallek M. Report on the 1st international workshop of the German competence network malignant lymphomas. Onkologie. 2007 May;30(5):265-73. Epub 2007 Apr 25.
Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol. 2007 May 1;25(13):1722-31. Epub 2007 Mar 26.
Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706-14.
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol. 2007 Jun;35(6):920-30.
Hausherr A, Tavares R, Schäffer M, Obermeier A, Miksch C, Mitina O, Ellwart J, Hallek M, Krause G. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene. 2007 Jul 26;26(34):4987-98. Epub 2007 Feb 19.
Hallek M. Physiologic evaluation in the elderly prior to treatment with chemotherapy. Clin Adv Hematol Oncol. 2007 Aug;5(8):620-1.
Eichhorst B, Hallek M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol. 2007 Sep;20(3):469-77.
Draube A, Chemnitz JM, Wickenhauser C, Staib P, Hallek M, Kreuzer KA. Cytomorphologic signs of severe pernicious anemia obscured in a patient with heterozygous hemoglobin Stanleyville II. Eur J Haematol. 2007 Oct;79(4):360-2. Epub 2007 Aug 3.
Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805.
Hallek M, Hiddemann W. Altern und Innere Medizin. Internist (Berl). 2007 Nov;48(11):1189.
Goede V, Hallek M. Ältere Patienten in klinischen Studien: Neue fitnessadaptierte Konzepte. Internist (Berl). 2007 Nov;48(11):1232-7.
Mitina O, Warmuth M, Krause G, Hallek M, Obermeier A. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann Hematol. 2007 Nov;86(11):777-85. Epub 2007 Aug 1.
Schweighofer CD, Fätkenheuer G, Staib P, Hallek M, Reiser M. Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis. Onkologie. 2007 Nov;30(11):564-6. Epub 2007 Oct 16.
Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007 Dec;27(6):965-74. Epub 2007 Dec 6.

2008

Eichhorst B, Hallek M. Frontline therapy of chronic lymphocytic leukemia. In O’Brien S, Gribben JG, eds. Chronic Lymphocytic Leukemia. New York, NY: Informa Health Care; 2008:121-139.
Jung N, Lehmann C, Hellmann M, Seifert H, Valter MM, Hallek M, Fätkenheuer G, Kochanek M. Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin’s abscess. Infect Dis Obstet Gynecol. 2008;2008:491401.
Schweighofer CD, Hallek M, Wendtner CM. Eradication of minimal residual disease in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2008 Jan;3(1):54-60.
Perabo L, Huber A, Märsch S, Hallek M, Büning H. Artificial evolution with adeno-associated viral libraries. Comb Chem High Throughput Screen. 2008 Feb;11(2):118-26.
Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin’s Lymphoma. Onkologie. 2008 Feb;31(1-2):49-51. Epub 2008 Jan 22.
Forster K, Obermeier A, Mitina O, Simon N, Warmuth M, Krause G, Hallek M. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Ann Hematol. 2008 Mar;87(3):183-93. Epub 2007 Oct 25.
Pallasch CP, Schwamb J, Königs S, Schulz A, Debey S, Kofler D, Schultze JL, Hallek M, Ultsch A, Wendtner CM. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008 Mar;22(3):585-92. Epub 2007 Dec 13.
White K, Büning H, Kritz A, Janicki H, McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, Nicklin SA, Baker AH. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther. 2008 Mar;15(6):443-51. Epub 2007 Nov 15.
Eichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii60-2.
Ostgathe C, Walshe R, Wolf J, Hallek M, Voltz R. A cost calculation model for specialist palliative care for patients with non-small cell lung cancer in a tertiary centre. Support Care Cancer. 2008 May;16(5):501-6. Epub 2007 Oct 2.
Borchmann P, Eichhorst B, Hellmann M, Hübel K, Kochanek M, Kreuzer KA, Reiser M, Hallek M. Hämatologie 2008. Dtsch Med Wochenschr. 2008 Jun;133(25-26):1400-4.
Hallek M; German CLL Study Group. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol. 2008 Jun;19 Suppl 4:iv51-3.
Hellmann M, Jung N, Owczarczyk K, Hallek M, Rubbert A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008 Jun;47(6):929-30. Epub 2008 Apr 14.
Jung N, Owczarczyk K, Hellmann M, Lehmann C, Fätkenheuer G, Hallek M, Rubbert A. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford). 2008 Jun;47(6):932-3. Epub 2008 Apr 16.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23.
Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med. 2008 Jul;10(7):717-33.
Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008 Jul;67(1):39-61. Epub 2008 Apr 23.
Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P; German CLL Study Group. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008 Jul;22(7):1377-86. Epub 2008 Apr 17.
Zuber C, Mitteregger G, Schuhmann N, Rey C, Knackmuss S, Rupprecht W, Reusch U, Pace C, Little M, Kretzschmar HA, Hallek M, Büning H, Weiss S. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol. 2008 Aug;89(Pt 8):2055-61.
Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M, Krause G. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood. 2008 Aug 15;112(4):1443-52. Epub 2008 Jun 12.
Kronenberger K, Nössner E, Frankenberger B, Wahl U, Dreyling M, Hallek M, Mocikat R. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia. J Immunother. 2008 Oct;31(8):723-30.
Owczarczyk K, Hellmann M, Fliedner G, Röhrs T, Maizus K, Passon D, Hallek M, Rubbert A. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis. 2008 Nov;67(11):1648-9.
Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H, Ultsch A, Wickenhauser C, Hallek M, Wendtner CM. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008 Nov 15;112(10):4213-9. Epub 2008 Aug 15.
Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec;49(12):2256-62.
Rüping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Müller C, Vehreschild JJ, Kochanek M, Fätkenheuer G, Bangard C, Ullmann AJ, Herr W, Kolbe K, Hallek M, Cornely OA. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother. 2008 Dec;62(6):1468-70. Epub 2008 Sep 28.

2009

Hacker J, Rendtorff T, Cramer P, Hallek M, Hilpert K, Kupatt C, Lohse M, Müller A, Schroth U, Voigt F, Zichy M. Biomedizinische Eingriffe am Menschen : Ein Stufenmodell zur ethischen Bewertung von Gen- und Zelltherapie. Berlin, Germany: Walter de Gruyter; 2009.
Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009.
Böhm M, Hallek M, Schmiegel W. Vorwort zur 6. Auflage. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:v.
Hallek M. Kapitel 11 – Onkologie. 11.1.9. Maligne Ergüsse. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:390-391.
Loquai C, Hallek M, Grabbe S. Kapitel 11 – Onkologie. 11.2.3. Malignes Melanom und andere Hauttumoren. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:407-414.
Dietlein M, Hallek M, Schicha H. Kapitel 11 – Onkologie. 11.2.8. Schilddrüsenkarzinome. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:451-454.
Beier D, Hallek M, Bogdahn U. Kapitel 11 – Onkologie. 11.2.9. Primäre ZNS-Tumoren. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:454-457.
Hallek M. Kapitel 11 – Onkologie. 11.2.10. Internistische Tumortherapie. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009:458-459.
Kreuzer KA, Hallek M. Kapitel 12 – Hämatologie. 12.1. Grundlagen der Hämatopoese. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009: 462-465.
Kreuzer KA, Hallek M. Kapitel 12 – Hämatologie. 12.2.1. Grundlagen. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009: 465-466.
Kreuzer KA, Hallek M. Kapitel 12 – Hämatologie. 12.2.2. Zytogenetische Methoden. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009: 466-468.
Kreuzer KA, Hallek M. Kapitel 12 – Hämatologie. 12.2.3. Molekularbiologische Analysen. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009: 468-472.
Reiser M, Hallek M. Kapitel 12 – Hämatologie. 12.5.4. Chronische lymphatische Leukämie. In Böhm M, Hallek M, Schmiegel W, Eds. Innere Medizin. Sixth Edition. Munich, Germany: Urban & Fischer; 2009: 535-537.
Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:440-9.
Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica. 2009 Jan;94(1):150-2. Epub 2008 Nov 10.
Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. Epub 2008 Oct 30.
Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009 Feb;50(2):171-8.
Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol. 2009 Feb;88(2):121-32. Epub 2008 Aug 6.
Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009 Mar;144(6):818-31. Epub 2009 Jan 8.
Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol. 2009 Mar;82(3):165-75. Epub 2008 Nov 20.
Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, Wendtner CM. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res. 2009 Mar;33(3):460-4. Epub 2008 Oct 5.
Fingerle-Rowson G, Kaleswarapu DR, Schlander C, Kabgani N, Brocks T, Reinart N, Busch R, Schütz A, Lue H, Du X, Liu A, Xiong H, Chen Y, Nemajerova A, Hallek M, Bernhagen J, Leng L, Bucala R. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol. 2009 Apr;29(7):1922-32. Epub 2009 Feb 2.
Klein F, Hallek M. Schwächt die Entfernung nicht befallener Lymphknoten eines Krebsherdes die immunologische Abwehr? Dtsch Med Wochenschr. 2009 Apr;134(16):834. Epub 2009 Apr 7.
Eichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:102-4. https://doi.org/10.1093/annonc/mdp142
Kunze M, Huber A, Krajewski A, Lowden E, Schuhmann N, Buening H, Hallek M, Noack M, Perabo L. Efficient gene transfer to periodontal ligament cells and human gingival fibroblasts by adeno-associated virus vectors. J Dent. 2009 Jul;37(7):502-8. Epub 2009 Apr 11. https://doi.org/10.1016/j.jdent.2009.03.001
Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009 Aug 20;27(24):3994-4001. Epub 2009 Jul 13.
Elter T, Stipanov M, Heuser E, von Bergwelt-Baildon M, Bloch W, Hallek M, Baumann F. Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma? Int J Hematol. 2009 Sep;90(2):199-204. Epub 2009 Jul 24.
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24;114(13):2589-97. Epub 2009 Jul 30.
Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 2009 Oct 8;114(15):3255-64. Epub 2009 Aug 19.
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009 Oct 15;114(16):3382-91. Epub 2009 Jul 15.
Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009 Nov;23(11):2007-17. Epub 2009 Jul 30.
Ernstmann N, Neumann M, Ommen O, Galushko M, Wirtz M, Voltz R, Hallek M, Pfaff H. Determinants and implications of cancer patients’ psychosocial needs. Support Care Cancer. 2009 Nov;17(11):1417-23. Epub 2009 Mar 13.
Hallek M. New menus for CLL treatment. Oncology (Williston Park). 2009 Nov 15;23(12):1046, 1051, 1056.
Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009 Nov 19;114(21):4675-86. Epub 2009 Sep 21.
Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, Perabo L, Quadt-Humme S, Odenthal M, Hallek M, Büning H. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J Gene Med. 2009 Dec;11(12):1103-13.
Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009 Dec 3;114(24):4919-27. Epub 2009 Sep 11.

2010

Kohl V, Müller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJ. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010 Jan;54(1):207-12. Epub 2009 Oct 26.
Maersch S, Huber A, Büning H, Hallek M, Perabo L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology. 2010 Feb 5;397(1):167-75. Epub 2009 Nov 18.
Böll B, Eichenauer DA, Von Tresckow B, Peine D, Hallek M, Engert A, Hübel K. Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. Leuk Lymphoma. 2010 Mar;51(3):562-4.
Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 Mar;24(3):500-11. Epub 2009 Dec 24.
Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2010 Mar;23(1):85-96.
Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010 Apr;12(4):326-35.
Eichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v162-4.
Gaertner J, Wolf J, Scheicht D, Frechen S, Klein U, Hellmich M, Ostgathe C, Hallek M, Voltz R. Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project. J Palliat Med. 2010 Jun;13(6):727-32.
Saech J, Owczarczyk K, Rösgen S, Petereit H, Hallek M, Rubbert-Roth A. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis. 2010 Jun;69(6):1254-5. Epub 2009 Sep 9.
Schievenbusch S, Strack I, Scheffler M, Nischt R, Coutelle O, Hösel M, Hallek M, Fries JW, Dienes HP, Odenthal M, Büning H. Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis. Mol Ther. 2010 Jul;18(7):1302-9. Epub 2010 Apr 27.
Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010 Jul;65(7):1466-71. Epub 2010 Apr 21.
Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F, Uhrmacher S, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res. 2010 Jul 1;16(13):3390-8. Epub 2010 Jun 22.
Hübel K, Cremer B, Heuser E, von Strandmann EP, Hallek M, Hansen HP. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2010 Aug;23(4):215-9. Epub 2010 Jul 8.
Königs SK, Pallasch CP, Lindner LH, Schwamb J, Schulz A, Brinker R, Claasen J, Veldurthy A, Eibl H, Hallek M, Wendtner CM. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res. 2010 Aug;34(8):1064-9. Epub 2010 Jan 21.
Hellmann M, Hallek M. Störungen der Thrombozytenfunktion. Internist (Berl). 2010 Sep;51(9):1085.
Hellmann M, Hallek M, Scharrer I. Thrombotisch-thrombozytopenische Purpura. Internist (Berl). 2010 Sep;51(9):1136, 1138-44.
Schuhmann NK, Pozzoli O, Sallach J, Huber A, Avitabile D, Perabo L, Rappl G, Capogrossi MC, Hallek M, Pesce M, Büning H. Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors. Exp Hematol. 2010 Sep;38(9):707-17. Epub 2010 May 4.
Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010 Oct;89(10):1029-33. Epub 2010 Apr 27.
Gaertner J, Wolf J, Ostgathe C, Toepelt K, Glossmann JP, Hallek M, Voltz R. Specifying WHO recommendation: moving toward disease-specific guidelines. J Palliat Med. 2010 Oct;13(10):1273-6.
Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010 Oct;21 Suppl 7:vii154-64.
Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, Hallek M, Rubbert A. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol. 2010 Oct;29(10):1169-73. Epub 2010 Jun 9.
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74.
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1.
Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010 Oct 10;28(29):4473-9. Epub 2010 Aug 9.
Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010 Oct 26;103(9):1407-14. Epub 2010 Oct 5.
Hallek M, Manns MP. Multimodale Therapie ausgewählter Tumorerkrankungen. Internist (Berl). 2010 Nov;51(11):1347.
Hacker U, Hallek M, Kubicka S. Multimodale Therapie des kolorektalen Karzinoms. Internist (Berl). 2010 Nov;51(11):1366-73. https://doi.org/10.1007/s00108-010-2671-9
Märsch S, Huber A, Hallek M, Büning H, Perabo L. A novel directed evolution method to enhance cell-type specificity of adeno-associated virus vectors. Comb Chem High Throughput Screen. 2010 Nov;13(9):807-12. https://doi.org/10.2174/138620710792927385
von Bergwelt-Baildon M, Hallek MJ, Shimabukuro-Vornhagen AA, Kochanek M. CCC meets ICU: redefining the role of critical care of cancer patients. BMC Cancer. 2010 Nov 8;10:612.
Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S; European Research Initiative on CLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010 Dec;24(12):2072-9. Epub 2010 Sep 23.
Shehata M, Demirtas D, Schnabl S, Hilgarth M, Hubmann R, Fonatsch C, Schwarzinger I, Hopfinger G, Eigenberger K, Heintel D, Porpaczy E, Vanura K, Hauswirth A, Schwarzmeier JD, Gaiger A, Stilgenbauer S, Hallek M, Bilban M, Jäger U. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia. 2010 Dec;24(12):2122-7. Epub 2010 Oct 22.
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010 Dec 15;2(62):62ra93.

2011

Goede V, Eichhorst B, Hallek M. Therapy of chronic lymphocytic leukemia: front‐line and salvage. In Faderl S, Kantarjian H, Eds. Leukemias: Principles and Practice of Therapy. Chichester, UK: Wiley-Blackwell; 2011: 308-314.
Büning H, Bolyard CM, Hallek M, Bartlett JS. Modification and labeling of AAV vector particles. Methods Mol Biol. 2011;807:273-300.
Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med. 2011;17(7-8):619-27. Epub 2011 Apr 14.
Schmoll HJ, Hallek M. Perspectives for onkologie. Onkologie. 2011;34(12):659. Epub 2011 Nov 25.
Cremer B, Sandmaier BM, Bethge W, Lange T, Goede V, Holtick U, Hallek M, Hübel K. Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. Onkologie. 2011;34(12):710-5. Epub 2011 Nov 23.
Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. Epub 2010 Oct 19.
Frenzel LP, Patz M, Pallasch CP, Brinker R, Claasen J, Schulz A, Hallek M, Kashkar H, Wendtner CM. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol. 2011 Jan;152(2):191-200. Epub 2010 Nov 23.
Hallek M, Lehnert H, Voltz R. Was ist Palliativmedizin? Internist (Berl). 2011 Jan;52(1):5-6.
Gärtner J, Wolf J, Voltz R, Hallek M. Onkologie und Palliativmedizin. Internist (Berl). 2011 Jan;52(1):15-6, 18-9.
Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 2011 Jan;25(1):1-9. Epub 2010 Nov 20.
Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011 Jan;96(1):156-62. Epub 2010 Nov 3.
Krause G, Hallek M. On the assessment of dasatinib-induced autophagy in CLL. Leuk Res. 2011 Jan;35(1):137-8. Epub 2010 Oct 14.
Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res. 2011 Jan 1;17(1):19-30.
Stahnke S, Lux K, Uhrig S, Kreppel F, Hösel M, Coutelle O, Ogris M, Hallek M, Büning H. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology. 2011 Jan 5;409(1):77-83. Epub 2010 Oct 25.
Razavi R, Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 2011 Jan 15;17(2):286-93. Epub 2010 Nov 19.
Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner CM, Klein C, Umana P, Hallek M, Krause G. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011 Feb;152(3):295-306. Epub 2010 Dec 13.
Zabel P, Hallek M. Bronchialkarzinome. Internist (Berl). 2011 Feb;52(2):123-4.
Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011 Feb 3;117(5):1516-21. Epub 2010 Nov 24.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011 Feb 10;117(6):1817-21. Epub 2010 Dec 7.
Krings Rocha C, Wendtner CM, Hallek M, Kreuzer KA. Conventional cytogenetics in chronic lymphocytic leukemia (CLL). Leuk Res. 2011 Mar;35(3):e25. Epub 2010 Nov 11.
Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging. 2011 Mar 1;28(3):163-76.
Rocha CK, Praulich I, Gehrke I, Hallek M, Kreuzer KA. A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report. Mol Cytogenet. 2011 Apr 1;4(1):8.
Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. Epub 2011 Jan 13.
Elter T, Hallek M, Montillo M. Alemtuzumab: what is the secret to safe therapy? Clin Adv Hematol Oncol. 2011 May;9(5):364-73.
Rüping MJ, Müller C, Vehreschild JJ, Böhme A, Mousset S, Harnischmacher U, Frommolt P, Wassmer G, Drzisga I, Hallek M, Cornely OA. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses. 2011 May;54(3):230-3.
Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D, Platzbecker U, Rodríguez-Macías G, Wermke M, Holtick U, Balsalobre P, Middeke JM, Shayegi N, Chemnitz JM, Krause A, Gruner N, Füssel M, Schetelig J, Thiede C, Ehninger G, Hallek M, Díez-Martín JL, Bornhäuser M. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia. 2011 May;25(5):880-3. Epub 2011 Feb 11.
Zander T, Hallek M. Thyrosinkinaseinhibitoren in der Onkologie. Internist (Berl). 2011 May;52(5):595-600.
Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, Buettner R, Ko YD, Ullrich RT, Smit E, Boellaard R, Lammertsma AA, Hallek M, Jacobs AH, Schlesinger A, Schulte K, Querings S, Stoelben E, Neumaier B, Thomas RK, Dietlein M, Wolf J. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011 May 1;29(13):1701-8. Epub 2011 Mar 21.
Gaertner J, Wolf J, Hallek M, Glossmann JP, Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy–a disease specific approach. Support Care Cancer. 2011 Jul;19(7):1037-43. Epub 2011 Mar 24.
Lilienthal N, Prinz C, Peer-Zada AA, Doering M, Ba LA, Hallek M, Jacob C, Herling M. Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic ‘sensor/effector’ compounds. Leuk Lymphoma. 2011 Jul;52(7):1407-11. Epub 2011 Mar 29.
Zander T, Hallek M. Erratum zu: Thyrosinkinaseinhibitoren in der Onkologie. Internist (Berl). 2011 Jul 10.
Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22(Suppl 6):vi50-4.
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10;29(26):3559-66. Epub 2011 Aug 15.
Gehrke I, Razavi R, Poll-Wolbeck SJ, Berkessel A, Hallek M, Kreuzer KA. The Antineoplastic Effect of Nitric Oxide-Donating Acetylsalicylic Acid (NO-ASA) in Chronic Lymphocytic Leukemia (CLL) Cells is Highly Dependent on its Positional Isomerism. Ther Adv Hematol. 2011 Oct;2(5):279-89.
Uhrmacher S, Schmidt C, Erdfelder F, Poll-Wolbeck SJ, Gehrke I, Hallek M, Kreuzer KA. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk Res. 2011 Oct;35(10):1360-6. Epub 2011 Apr 30.
Cornely OA, Vehreschild JJ, Vehreschild MJ, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother. 2011 Dec;55(12):5798-803. 2011 Sep 12.
Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011 Dec;12(13):1204-13. Epub 2011 Oct 10.

2012

Krause G, Kuckertz M, Kerwien S, Patz M, Hallek M. In vitro sensitivity testing in the assessment of anti-CLL drug candidates. In Oppezzo P, Ed. Chronic Lymphocytic Leukemia. London, UK: IntechOpen; 2012:323-338. https://doi.org/10.5772/27087
Koehler P, Schmidt P, Hombach AA, Hallek M, Abken H. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol. 2012;2012:595060. Epub 2011 Aug 8. https://doi.org/10.1155/2012/595060
Marmé D, Hallek M. Personalized cancer medicine. Onkologie. 2012;35(Suppl 1):2. Epub 2012 Jan 20. https://doi.org/10.1159/000335980
Kuckertz M, Patz M, Veldurthy A, Gehrke I, Claasen J, Frenzel LP, Wendtner CM, Hallek M, Krause G. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie. 2012;35(7-8):420-6. Epub 2012 Jul 6.
Hallek M. Professor Hans-Joachim Schmoll – 10 years editor-in-chief of Onkologie. Onkologie. 2012;35(12):728. Epub 2012 Nov 21.
Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol. 2012 Jan;91(1):47-55. Epub 2011 May 17.
Cramer P, Hallek M. Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nat Rev Clin Oncol. 2012 Jan 10;9(2):72-4.
Hösel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M, Knolle P, Hallek M, Protzer U, Büning H. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012 Jan;55(1):287-97.
Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008078.
Uhrig S, Coutelle O, Wiehe T, Perabo L, Hallek M, Büning H. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 2012 Feb;19(2):210-8. Epub 2011 Jun 9.
Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents. 2012 Feb;39(2):130-4. Epub 2011 Dec 12.
Gaertner J, Wolf J, Frechen S, Klein U, Scheicht D, Hellmich M, Toepelt K, Glossmann JP, Ostgathe C, Hallek M, Voltz R. Recommending early integration of palliative care – does it work? Support Care Cancer. 2012 Mar;20(3):507-13. Epub 2011 Feb 19.
Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, Kerwien S, Kuckertz M, Brinker R, Claasen J, Frenzel LP, Wendtner CM, Heider KH, Hallek M. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia. 2012 Mar;26(3):546-9. Epub 2011 Sep 2.
Manns MP, Schellong SM, Hallek M. Sonographie in der Inneren Medizin. Internist (Berl). 2012 Mar;53(3):249-50.
Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar;53(3):417-23. Epub 2011 Nov 15.
Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012 Mar 20;30(9):980-8. Epub 2012 Feb 13.
Kofler DM, Gawlik BB, Elter T, Gianella-Borradori A, Wendtner CM, Hallek M. Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia. 2012 Apr;26(4):841-4. Epub 2011 Oct 7.
Kümmerle T, Fätkenheuer G, Hallek M. Tollwut-Impfung: wann und wie? Dtsch Med Wochenschr. 2012 Apr;137(15):789-92. Epub 2012 Apr 10.
Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012 May 3;119(18):4101-7. Epub 2012 Mar 6.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4.
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; German CLL Study Group. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood. 2012 May 24;119(21):4851-9. Epub 2012 Apr 5.
Hallek M. FCA: forget chemoimmunotherapy with alemtuzumab? Blood. 2012 May 31;119(22):5059-60.
Isfort S, Cramer P, Hallek M. Novel and emerging drugs for chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2012 Jun;12(5):471-83.
Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012 Jun;68(6):987-95.
Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Haematol. 2012 Jul;158(2):238-241. Epub 2012 May 10.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012 Jul;26(7):1458-61. Epub 2012 Feb 2. https://doi.org/10.1038/leu.2012.25
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31.
Rath T, Hackenbroch M, Saech J, Hallek M, Rubbert A. Longterm remission of more than 5 years in a patient with progressive multifocal leucoencephalopathy and sarcoidosis. Clin Neurol Neurosurg. 2012 Sep;114(7):1057-8. Epub 2012 Mar 3.
Hamprecht A, Buchheidt D, Vehreschild JJ, Cornely OA, Spiess B, Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T, Steinbach A, Bos B, Hallek M, Vehreschild MJ. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill. 2012 Sep 6;17(36):20262.
Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16. Epub 2012 Aug 6.
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012 Oct;44(10):1104-10. Epub 2012 Sep 2.
Ullrich RT, Zander T, Wolf J, Hallek M. Personalisierte Therapie von Lungenkrebs. Dtsch Med Wochenschr. 2012 Oct;137(42):2179-80. Epub 2012 Oct 10.
Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch CP, Hallek M, Wendtner CM, Frenzel LP. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood. 2012 Nov 8;120(19):3978-85. Epub 2012 Aug 27.
Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079.
Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2549-52. Epub 2012 May 15.
Hallek M, Schröter T. Die Zukunft der internistischen Weiterbildung in Deutschland. Dtsch Med Wochenschr. 2012 Dec;137(49):2591-4. Epub 2012 Nov 27.
Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012 Dec;40(6):613-9. Epub 2012 Jun 5.
Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Cancer Immunol Immunother. 2012 Dec;61(12):2367-73. Epub 2012 Oct 23.
Baumann FT, Zimmer P, Finkenberg K, Hallek M, Bloch W, Elter T. Influence of endurance exercise on the risk of pneumonia and Fever in leukemia and lymphoma patients undergoing high dose chemotherapy. A pilot study. J Sports Sci Med. 2012 Dec 1;11(4):638-42.
Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012 Dec 6;120(24):4783-94. Epub 2012 Oct 9.

2013

Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:138-50.
Hallek M, Knauf W, Dreyling M, Trümper L. Aktuelle und künftige Indikationen mit Bendamustin: chronische lymphatische Leukämie, indolente Lymphome, Mantelzell-Lymphome und diffuse großzellige B-Zell-Lymphome. Onkologie. 2013;36(Suppl 1):11-8. Epub 2013 Jan 28.
Ihrig K, Fath B, Fuchs M, Hallek M, Marschner N, Naumann R, Röllig C, Saussele S, Tesch H, Gökbuget N. Akademische multizentrische Studien im Fokus: Auswirkungen der Arzneimittelgesetzgebung auf Therapieoptimierungsstudien in der Hämatologie/Onkologie. Onkologie. 2013;36(Suppl 2):23-8.
Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, Buchholz CJ. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther. 2013 Jan;21(1):109-18. Epub 2012 Sep 11.
Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013 Jan;27(1):142-9. Epub 2012 Jul 31.
Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, Rudolph C, Ristovska V, Velmans T, Mueller C, Reiners KS, von Strandmann EP, Krause G, Montesinos-Rongen M, Schlegelberger B, Herling M, Hallek M, Fingerle-Rowson G. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood. 2013 Jan 31;121(5):812-21. Epub 2012 Nov 1.
Hallek M. Große Bedeutung einer unabhängigen klinischen Forschung für die Evaluation neuer Therapieverfahren. Dtsch Med Wochenschr. 2013 Feb;138(5):167. Epub 2013 Jan 22.
Hallek M, Wolf J. Personalisierte Therapie. Internist (Berl). 2013 Feb;54(2):145-6.
Stilgenbauer S, Hallek M. Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist (Berl). 2013 Feb;54(2):164, 166-70.
Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, Rozen S, Gopalakrishnan V, Schaper F, Hallek M, Boussioutas A, Tan P, Jarnicki A, Ernst M. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest. 2013 Feb;123(2):767-81. Epub 2013 Jan 16.
Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013 Feb 10;31(5):e59-63. Epub 2012 Dec 26.
Suárez I, Langerbeins P, Mattonet C, Birtel A, Fresen MM, Kochanek M, Hallek M, Fätkenheuer G. Morbiditäts- und Mortalitätskonferenz in der Inneren Medizin: Erfahrungen an der Uniklinik Köln. Dtsch Med Wochenschr. 2013 Mar;138(13):655-7. Epub 2013 Mar 19.
Böttcher S, Hallek M, Ritgen M, Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin North Am. 2013 Apr;27(2):267-88.
Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G, Engelke A, Humphrey K, Wenger M, Hallek M. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia. 2013 Apr;27(5):1172-4. Epub 2012 Aug 31.
Würthwein G, Cornely OA, Trame MN, Vehreschild JJ, Vehreschild MJ, Farowski F, Müller C, Boos J, Hempel G, Hallek M, Groll AH. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother. 2013 Apr;57(4):1664-71. Epub 2013 Jan 18.
Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22.
Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood. 2013 May 2;121(18):3658-65. Epub 2013 Mar 18.
Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G, Herling M. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood. 2013 May 16;121(20):4126-36. Epub 2013 Apr 1.
Hübel K, Hallek M. Monoklonale Gammopathie unklarer Signifikanz und monoklonale B-Lymphozytose. Internist (Berl). 2013 Jun;54(6):709-14.
Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas J, Chen S, Reinhardt HC. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med. 2013 Jun 12;5(189):189ra78.
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013 Jun 15;119(12):2258-67. Epub 2013 Mar 19.
Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner CM, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stilgenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma. 2013 Aug;54(8):1821-2. Epub 2013 Jun 12.
Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013 Aug 15;122(7):1266-70. Epub 2013 Jul 2.
Theurich S, Wennhold K, Wedemeyer I, Rothe A, Hübel K, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity. Transplantation. 2013 Aug 15;96(3):e16-8.
Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. PLoS One. 2013 Aug 23;8(8):e72107.
Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. 2013 Sep;27(9):1949-52. Epub 2013 Jun 21.
Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013 Sep;88(9):803-16.
Hallek M, von Bergwelt-Baildon M. Onkologische und hämatologische Notfälle. Intensivmedizinisches Management. Internist (Berl). 2013 Sep;54(9):1041-2.
Kochanek M, Böll B, Hallek M, von Bergwelt-Baildon M. Neutropenie und Sepsis. Internist (Berl). 2013 Sep;54(9):1061-9. https://doi.org/10.1007/s00108-013-3258-z
von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Hallek M, Kochanek M. Intensivmedizinisches Management hämatologischer und onkologischer Patienten. Internist (Berl). 2013 Sep;54(9):1080-6.
Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer. 2013 Sep 17;109(6):1408-13. Epub 2013 Aug 20.
Maurer C, Hallek M. Chronische lymphatische Leukämie. Dtsch Med Wochenschr. 2013 Oct;138(42):2153-66. Epub 2013 Oct 8.
Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von Bergwelt-Baildon M. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. Epub 2013 Apr 2.
Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013 Nov 10;31(32):4115-22. Epub 2013 Sep 23.
Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013 Nov 28;122(23):3723-34. Epub 2013 Sep 24.

2014

Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, Hallek M, Herling M. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1. Curr Cancer Drug Targets. 2014;14(8):700-12.
Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 2014 Jan 30;156(3):590-602.
Hallek M. Deutschland soll ein international sichtbarer Innovationsstandort in der Gesundheitsforschung warden. Dtsch Med Wochenschr. 2014 Feb;139(6):227. Epub 2014 Jan 28.
Heimann SM, Cornely OA, Vehreschild MJ, Glossmann J, Kochanek M, Kreuzer KA, Hallek M, Vehreschild JJ. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses. 2014 Feb;57(2):90-7. Epub 2013 Jun 24.
Vyas M, Koehl U, Hallek M, von Strandmann EP. Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. Trends Mol Med. 2014 Feb;20(2):72-82. Epub 2013 Nov 19.
Cramer P, Bahlo J, Eichhorst B, Fischer K, Hallek M. Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. Leuk Res. 2014 Mar;38(3):284-5. Epub 2013 Dec 1.
Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Dürkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, Pogge von Strandmann E. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin’s lymphoma. J Pathol. 2014 Mar;232(4):405-14.
von Tresckow B, Boell B, Eichenauer D, Beschorner D, Knop S, Goebeler ME, Chemnitz JM, Hallek M, Engert A, Huebel K. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial. Leuk Lymphoma. 2014 Mar;55(3):695-7. Epub 2013 Jul 29.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8.
Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Piekarek M, Brinkmann K, Seeger JM, Liwschitz M, Miwa S, Hallek M, Krönke M, Trifunovic A, Eming SA, Wiesner RJ, Hacker UT, Kashkar H. Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol Med. 2014 May;6(5):624-39.
Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rübsam M, Huber A, Chiorini J, Almarza D, Eming SA, Ulus H, Nishimura S, Hacker UT, Hallek M, Niessen CM, Büning H. Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther. 2014 May;22(5):929-39. Epub 2014 Jan 28.
Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46. Epub 2014 Mar 31.
Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014 May 22;123(21):3247-54. Epub 2014 Mar 20.
Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014 Jun;99(6):965-72. https://doi.org/10.3324/haematol.2013.096107
Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, Stilgenbauer S, Döhner H, Westermann A, Wendtner CM, Eichhorst B, Hallek M; German CLL Study Group. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014 Jun;99(6):1095-100. Epub 2014 Feb 28.
Goede V, Fischer K, Hallek M. Chemoimmunotherapy for chronic lymphocytic leukemia. Author reply. N Engl J Med. 2014 Jun 12;370(24):2348-9.
Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014 Jun 15;134(12):2829-40. Epub 2013 Nov 29.
Pallasch CP, Hallek M. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia. Semin Hematol. 2014 Jul;51(3):235-48. Epub 2014 May 15.
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62. Epub 2014 May 5.
Shimabukuro-Vornhagen A, Schlößer HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, Stippel DL, Hölscher AH, Eidt S, Hallek M, Theurich S, von Bergwelt-Baildon MS. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget. 2014 Jul 15;5(13):4651-64.
Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):420-5. Epub 2014 Jun 10.
Peiffer L, Poll-Wolbeck SJ, Flamme H, Gehrke I, Hallek M, Kreuzer KA. Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol. 2014 Aug;140(8):1283-93. Epub 2014 May 4.
Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 2014 Sep;25(9):1800-6. Epub 2014 Jun 13.
Hallek M. „Choosing Wisely“ – Vermeiden unnötiger medizinischer Maßnahmen. Dtsch Med Wochenschr. 2014 Oct;139(40):1975. Epub 2014 Sep 25.
Märker-Hermann E, Hallek M. Zufällige Laborbefunde in der Inneren Medizin. Internist (Berl). 2014 Oct;55(10):1129-30.
Kreuzer KA, Hallek M. Zufallsbefund Lymphozytose. Von der Normvariante bis zur Leukämie. Internist (Berl). 2014 Oct;55(10):1131-8. https://doi.org/10.1007/s00108-014-3488-8
Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. https://doi.org/10.1182/blood-2014-07-586610
Kusch M, Labouvie H, Hein-Nau B, Schwarzkamp U, Wolf J, Hallek M. Integrierte Psychoonkologie. Implementierung eines psychoonkologischen Versorgungsprogramms am Centrum für Integrierte Onkologie Köln Bonn, Standort Köln. Dtsch Med Wochenschr. 2014 Nov;139(46):2357-60. Epub 2014 Nov 4.
von Bergwelt-Baildon M, Holtick U, Hallek MJ, Scheid C. Transplantation hämatopoetischer Stammzellen. Knochenmark und Blutstammzellen. Internist (Berl). 2014 Nov;55(11):1306-12. https://doi.org/10.1007/s00108-014-3509-7
Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, Kochanek M, Blaschke F, Pallasch C, Holtick U, Scheid C, Theurich S, Hallek M, von Bergwelt-Baildon MS. Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity. J Immunol. 2014 Nov 15;193(10):5294-305. Epub 2014 Oct 13.
Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014 Dec;89(12):E239-43. Epub 2014 Sep 26.
Zimmer P, Baumann FT, Bloch W, Schenk A, Koliamitra C, Jensen P, Mierau A, Hülsdünker T, Reinart N, Hallek M, Elter T. Impact of exercise on pro inflammatory cytokine levels and epigenetic modulations of tumor-competitive lymphocytes in Non-Hodgkin-Lymphoma patients-randomized controlled trial. Eur J Haematol. 2014 Dec;93(6):527-32. Epub 2014 Jun 28.
Rawstron A, Fazi C, Villamor N, Delgado J, Letestu R, Cymbalista F, Palacio C, Bosch F, De Tute RM, Liptrot S, O’Brien D, Spacek M, Dobber J, Kater AP, Gambell PC, Westerman DA, Soosapilla A, Mulligan SP, Lozanski G, Lin K, Pettitt AR, Brachtl G, Egle A, Williamson DW, Sanders CM, Robins H, Boysen J, Shanafelt TD, Hanson CA, Jorgensen JL, Wierda WG, Yuan C, Stetler-Stevenson M, Rassenti L, Broome HE, Kipps TJ, Hauwel M, Marinov I, Craig FE, Josep N, Moreno C, Stehlikova O, Doubek M, Pospisilova S, Kreuzer KA, Hallek M, Hillmen P, Montserrat E, Ghia P. A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood. 2014 Dec 6;124(21):1976-1976.
Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17.

2015

Hallek M. Prinzipien der Tumorbiologie. In Lehnert H, Ed. DGIM Innere Medizin. Berlin, Germany: Springer; 2015.
Mallmann P, Hallek M. Uterussarkome. In Lehnert H, Ed. DGIM Innere Medizin. Berlin, Germany: Springer; 2015.
Hallek M. One year of Oncology Research and Treatment. Oncol Res Treat. 2015;38(1-2):7. Epub 2015 Feb 3.
Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015;11(1):51-9.
Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11(13):1895-903.
Kutsch N, Hallek M, Eichhorst B. Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Feb;56(2):285-92. Epub 2014 Jun 27.
Zimmer P, Mierau A, Bloch W, Strüder HK, Hülsdünker T, Schenk A, Fiebig L, Baumann FT, Hahn M, Reinart N, Hallek M, Elter T. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma. 2015 Feb;56(2):347-52. Epub 2014 Jun 5.
Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br J Cancer. 2015 Feb 3;112(3):495-503. Epub 2015 Jan 6.
Hallek M. Klinische Forschung in Deutschland: Bürokratieabbau jetzt wagen! Dtsch Med Wochenschr. 2015 Apr;140(7):463-4. Epub 2015 Mar 31.
Hallek M. Molekulare Ursachen der Leukämien. Systematische klinische und präklinische Forschung. Internist (Berl). 2015 Apr;56(4):331-2.
Eichhorst B, Hallek M. Chronische lymphatische Leukämie. Therapiekonzepte im Wandel. Internist (Berl). 2015 Apr;56(4):374-80.
Huelsemann MF, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker HJ, Theurich S, von Bergwelt-Baildon M, Pallasch CP, Zahedi RP, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel LP. Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia. 2015 Apr;29(4):981-4. Epub 2014 Nov 7.
Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. https://doi.org/10.1016/S0140-6736(14)61469-0
Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015 May;90(5):446-60. https://doi.org/10.1002/ajh.23979
Holtick U, Chemnitz JM, Hallek M, Scheid C. Allogene Blutstammzelltransplantation – ein Überblick. Klin Monbl Augenheilkd. 2015 May;232(5):641-6. Epub 2015 May 19.
Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May;39(5):495-500. Epub 2015 Feb 7.
Berg V, Rusch M, Vartak N, Jüngst C, Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek M, Wendtner CM, Frenzel LP. miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL. Blood. 2015 May 7;125(19):2948-57. Epub 2015 Feb 10.
Goede V, Hallek M. Towards improved frontline treatment of CLL in the elderly. Lancet. 2015 May 9;385(9980):1814-5. Epub 2015 Apr 14.
Langerbeins P, Maurer C, Cramer P, Eichhorst B, Hallek M. Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes. Leuk Lymphoma. 2015 Jun;56(6):1575-6. Epub 2015 May 12.
Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun;56(6):1585-92. Epub 2014 Nov 20.
Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer. 2015 Jun 4;14:114. https://doi.org/10.1186/s12943-015-0378-1
Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD, Buettner R. Comprehensive analysis of disease-related genes in chronic lymphocytic leukemia by multiplex PCR-based next generation sequencing. PLoS One. 2015 Jun 8;10(6):e0129544.
Engel LA, Wittig S, Bock F, Sauerbier L, Scheid C, Holtick U, Chemnitz JM, Hallek M, Cursiefen C, Steven P. Meibography and meibomian gland measurements in ocular graft-versus-host disease. Bone Marrow Transplant. 2015 Jul;50(7):961-7. Epub 2015 Apr 20.
Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30.
Kochanek M, Böll B, Shimabukuro-Vornhagen A, Michels G, Barbara W, Hansen D, Hallek M, Fätkenheuer G, von Bergwelt-Baildon M. Personalbedarf einer Intensivstation unter Berücksichtigung geltender Hygienerichtlinien. Eine explorative Analyse. Dtsch Med Wochenschr. 2015 Jul;140(14):e136-41. Epub 2015 Jul 16.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015 Aug 6;524(7563):47-53. Epub 2015 Jul 13.
Baumann FT, Hallek M, Meyer J, Galvão DA, Bloch W, Elter T. Onkologische Trainings- und Bewegungstherapie (OTT). Ein personalisiertes Behandlungskonzept für Krebspatienten. Dtsch Med Wochenschr. 2015 Sep;140(19):1457-61. Epub 2015 Sep 24.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v78-84.
Hallek M. Anämien. Internist (Berl). 2015 Sep;56(9):969.
Fandrey J, Hallek M. Erythropoese: Physiologie, Pathophysiologie und Algorithmus zur Abklärung von Anämien. Internist (Berl). 2015 Sep;56(9):970-7.
Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C. Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality–a single institution experience. Ann Hematol. 2015 Oct;94(10):1717-25. Epub 2015 Aug 12.
Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003-14. Epub 2015 May 4.
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22;526(7574):525-30. Epub 2015 Oct 14.
Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica. 2015 Nov;100(11):1451-9. Epub 2015 Aug 27.
Goede V, Hallek M. Pharmacotherapeutic management of chronic lymphocytic leukaemia in patients with comorbidities: New agents, new hope. Drugs Aging. 2015 Nov;32(11):877-86.
Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42. Epub 2015 May 12.
Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology. 2015 Nov 9;5(5):e1100789.
Heimann SM, Vehreschild JJ, Cornely OA, Wisplinghoff H, Hallek M, Goldbrunner R, Böttiger BW, Goeser T, Hölscher A, Baldus S, Müller F, Jazmati N, Wingen S, Franke B, Vehreschild MJ. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015 Dec;43(6):707-14. Epub 2015 Jun 30.
Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G, Cartron G. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015 Dec 10;126(24):2646-9. Epub 2015 Oct 7.

2016

Bokemeyer C, Hallek M, Lüftner D, Weißinger F. Vorwort. Oncol Res Treat. 2016;39 Suppl 2:1. Epub 2016 Aug 31.
Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? Am Soc Clin Oncol Educ Book. 2016;35:e387-98.
Hallek M. Pathogenesis, diagnosis and treatment of chronic lymphocytic leukemia: exciting times. Oncol Res Treat. 2016;39(1-2):8. Epub 2016 Jan 22.
Cramer P, Hallek M, Eichhorst B. State-of-the-art treatment and novel agents in chronic lymphocytic leukemia. Oncol Res Treat. 2016;39(1-2):25-32. Epub 2016 Jan 22.
Al-Sawaf O, Fischer K, Eichhorst B, Hallek M. Targeted therapy of CLL. Oncol Res Treat. 2016;39(12):768-778. Epub 2016 Nov 15.
Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2016;57(3):596-603. Epub 2015 Oct 12. https://doi.org/10.3109/10428194.2015.1079314
Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789-96. Epub 2015 Oct 13. https://doi.org/10.3109/10428194.2015.1091933
Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1291-9. Epub 2016 Jan 14.
Cramer P, Langerbeins P, Eichhorst B, Hallek M. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol. 2016 Jan;96(1):9-18. Epub 2015 Nov 6.
Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt-Baildon M, Scheid C. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016 Jan;96(1):27-35. Epub 2015 Mar 16.
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15. Epub 2015 Oct 20.
Cramer P, Langerbeins P, Hallek M. Combination of targeted drugs to control chronic lymphocytic leukemia: harnessing the power of new monoclonal antibodies in combination with ibrutinib. Cancer J. 2016 Jan-Feb;22(1):62-6.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-211. Epub 2015 Dec 5.
Hallek M. Innovationsfonds: Die Chance muss genutzt werden! Dtsch Med Wochenschr. 2016 Feb;141(3):153-4. Epub 2016 Feb 3.
Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, Arnold R, Afanasyev B, Vigouroux S, Milpied N, Hallek M, Cornelissen JJ, Schwerdtfeger R, Polge E, Baron F, Esteve J, Gorin NC, Schmid C, Giebel S, Mohty M, Nagler A. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016 Feb;101(2):256-62. Epub 2015 Nov 12.
Hallek M. Innovationsfonds: Die Chance muss genutzt werden! Erratum. Dtsch Med Wochenschr. 2016 Mar;141(5):313. Epub 2016 Mar 3.
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6:e404.
Cramer P, Eichhorst B, Reinhardt HC, Hallek M. Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract Res Clin Haematol. 2016 Mar;29(1):111-121. Epub 2016 Aug 12.
Eichhorst B, Cramer P, Hallek M. Initial therapy of chronic lymphocytic leukemia. Semin Oncol. 2016 Apr;43(2):241-50. Epub 2016 Feb 9.
Hallek M. Übertherapie vermeiden: „Choosing wisely“-Empfehlungen werden unzureichend umgesetzt. Dtsch Med Wochenschr. 2016 Apr;141(8):530. Epub 2016 Apr 14. https://doi.org/10.1055/s-0041-111152
Hellmich S, Schreiber N, Fath B, Hallek M. Fortschritt durch vernetzte Strukturen. Herausforderungen für das Kompetenznetz Maligne Lymphome im Zeitalter der Präzisionsmedizin. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):454-64.
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O’Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr;30(4):929-36. Epub 2015 Dec 7.
Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M. Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma. J Clin Oncol. 2016 Apr 20;34(12):e110-6. Epub 2014 Oct 27.
Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016 Apr 20;34(12):1386-94. Epub 2016 Feb 29.
Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016 Apr 22;5(6):e1150399.
Cramer P, Langerbeins P, Fischer K, Eichhorst B, Hallek M, Goede V. Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all? Leuk Lymphoma. 2016 May;57(5):987-90.
Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016 May;57(5):1130-9. Epub 2015 Nov 20.
Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. Eur J Haematol. 2016 May;96(5):475-82. Epub 2015 Aug 25.
Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M. A novel recombinant anti-CD22 immunokinase delivers proapoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B cells. Mol Cancer Ther. 2016 May;15(5):971-84. Epub 2016 Jan 29.
Weinhold M, Shimabukuro-Vornhagen A, Franke A, Theurich S, Wahl P, Hallek M, Schmidt A, Schinköthe T, Mester J, von Bergwelt-Baildon M, Bloch W. Physical exercise modulates the homeostasis of human regulatory T cells. J Allergy Clin Immunol. 2016 May;137(5):1607-1610.e8. Epub 2016 Jan 7.
Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro. Oncotarget. 2016 May 24;7(21):30523-35.
Hasenfuß G, Märker-Hermann E, Hallek M, Sieber C. Klug entscheiden. Allem voran die Indikationsqualität. Internist (Berl). 2016 Jun;57(6):519-20.
Hasenfuß G, Märker-Hermann E, Hallek M, Fölsch UR. Klug entscheiden in der Inneren Medizin. Internist (Berl). 2016 Jun;57(6):521-6.
Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van’t Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia. 2016 Jun;30(6):1428-30. Epub 2015 Nov 24.
Krause G, Baki I, Kerwien S, Knödgen E, Neumann L, Göckeritz E, Landwehr T, Heider KH, Hallek M. Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors. Br J Haematol. 2016 Jun;173(5):791-4. Epub 2015 Aug 14.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-778. Epub 2016 May 10.
Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016 Jun 9;127(23):2847-55. Epub 2016 Mar 3.
Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016 Jul;101(7):879-83. Epub 2016 Apr 14.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-942. Epub 2016 May 20.
Zimmer P, Oberste M, Bloch W, Schenk A, Joisten N, Hartig P, Wolf F, Baumann FT, Garthe A, Hallek M, Elter T. Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome – Study protocol of a randomized placebo-controlled trial. Contemp Clin Trials. 2016 Jul;49:1-5. Epub 2016 May 31.
Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E. Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. Oncoimmunology. 2016 Jul 15;5(9):e1211220.
Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016 Jul 21;128(3):395-404. Epub 2016 May 25.
Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016 Jul 28;128(4):574-83. Epub 2016 May 27.
Chakupurakal G, García-Márquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. Eur J Haematol. 2016 Aug;97(2):121-7. Epub 2015 Nov 16.
Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016 Aug;30(8):1763-6. Epub 2016 Mar 4.
Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. J Hematol Oncol. 2016 Aug 3;9(1):65.
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. Epub 2016 Jun 14.
Daßler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert R, Tüting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C. RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology. 2016 Aug 19;5(10):e1219827.
Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullermann C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U. Patients with acute myeloid leukemia admitted to intensive care units: outcome analysis and risk prediction. PLoS One. 2016 Aug 30;11(8):e0160871.
Eichhorst B, Hallek M, Goede V. New treatment approaches in CLL: Challenges and opportunities in the elderly. J Geriatr Oncol. 2016 Sep;7(5):375-82. Epub 2016 Aug 1.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C. appendix 6: Chronic lymphocytic leukemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016 Sep;27(suppl 5):v143-v144.
Fischer J, Hamacher L, Fries J, Hallek M, Cornely OA, Kochanek M, Boell B. Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL. Ann Hematol. 2016 Sep;95(9):1569-70. Epub 2016 Jun 14.
Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur J Haematol. 2016 Sep;97(3):253-60. Epub 2016 Feb 9.
Groneck L, Quaas A, Hallek M, Zander T, Weihrauch MR. Ultrasound-guided core needle biopsies for workup of lymphadenopathy and lymphoma. Eur J Haematol. 2016 Oct;97(4):379-86. Epub 2016 Feb 26.
Lehnert H, Sieber C, Hallek M. Palliativmedizin. Internist (Berl). 2016 Oct;57(10):943-945.
Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B. Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL. Leukemia. 2016 Oct;30(10):2019-2025. Epub 2016 May 2.
O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13.
Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, Florin A, Wunderlich FT, Reinart N, Hallek M. LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia. Cancer Cell. 2016 Oct 10;30(4):610-622.
Hallek M. Behandlung von Leukämien Fortschritt durch gute präklinische und systematische klinische Forschung „made in Germany“. Drug Res (Stuttg). 2016 Nov;66(S 01):S28. Epub 2016 Nov 2.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016 Nov 1;34(31):3758-3765.
Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155.

2017

Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther. 2017 Jan 25;11:295-304.
Brocks T, Fedorchenko O, Schliermann N, Stein A, Moll UM, Seegobin S, Dewor M, Hallek M, Marquardt Y, Fietkau K, Heise R, Huth S, Pfister H, Bernhagen J, Bucala R, Baron JM, Fingerle-Rowson G. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. FASEB J. 2017 Feb;31(2):526-543. Epub 2016 Oct 19.
Chakupurakal G, Garcia-Marquez MA, Shimabukuro-Vornhagen A, Kluth S, Schlosser H, Theurich S, Scheid C, Hallek M, Holtick U, von Bergwelt-Baildon M. Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease. Eur J Haematol. 2017 Feb;98(2):128-133. Epub 2016 Nov 6.
Kron F, Kutsch N, Kostenko A, Dohle I, Glossmann JP, Müller D, Heimann SM, Bahlo J, von Bergwelt-Baildon M, Eichhorst B, Wolf J, Hallek M, Zander T. Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective. Eur J Haematol. 2017 Feb;98(2):169-176. Epub 2016 Nov 1.
Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Feb;58(2):399-407. Epub 2016 Jun 29.
Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani BN, Mohty M, Nagler A. Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Feb;23(2):278-284. Epub 2016 Nov 2.
Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15.
Shimabukuro-Vornhagen A, García-Márquez M, Fischer RN, Iltgen-Breburda J, Fiedler A, Wennhold K, Rappl G, Abken H, Lehmann C, Herling M, Wolf D, Fätkenheuer G, Rubbert-Roth A, Hallek M, Theurich S, von Bergwelt-Baildon M. Antigen-presenting human B cells are expanded in inflammatory conditions. J Leukoc Biol. 2017 Feb;101(2):577-587. Epub 2016 Aug 17.
Sauer M, Schuldner M, Hoffmann N, Cetintas A, Reiners KS, Shatnyeva O, Hallek M, Hansen HP, Gasser S, von Strandmann EP. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene. 2017 Feb 16;36(7):933-941. Epub 2016 Aug 1.
Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer. 2017 Feb 28;116(5):600-608. Epub 2017 Jan 31.
Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol. 2017 Mar;98(3):254-262. Epub 2016 Dec 1.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia. 2017 Mar;31(3):734-738. Epub 2016 Nov 2.
Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Ann Hematol. 2017 Mar;96(3):479-487. Epub 2016 Dec 1.
Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, von Strandmann EP. Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells. Haematologica. 2017 Mar;102(3):e100-e103. Epub 2016 Nov 17.
Tahmaz V, Gehlsen U, Sauerbier L, Holtick U, Engel L, Radojska S, Petrescu-Jipa VM, Scheid C, Hallek M, Gathof B, Cursiefen C, Steven P. Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J Ophthalmol. 2017 Mar;101(3):322-326. Epub 2016 Jun 6.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M. Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia. 2017 May;31(5):1177-1186. Epub 2016 Oct 24.
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 May 11;129(19):2702-2705. Epub 2017 Mar 21.
Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N. Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Ther Adv Hematol. 2017 Jun;8(6):197-205. Epub 2017 Mar 30.
Hallek M. Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun;35 Suppl 1:30-32.
Hasenfuß G, Märker-Hermann E, Hallek M, Sieber CC, Fölsch UR. Klug entscheiden – evidenzbasiert. Internist (Berl). 2017 Jun;58(6):525-526.
Fölsch UR, Hallek M, Raupach T, Hasenfuß G. Resonanz und Weiterentwicklung der Initiative Klug entscheiden. Internist (Berl). 2017 Jun;58(6):527-531.
Kron F, Kostenko A, Scheffler M, Müller D, Glossmann JP, Fischer R, Michels S, Nogova L, Hallek M, Zander T, Wolf J. Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer. 2017 Jun;108:134-139. Epub 2017 Mar 30.
Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017 Jul;58(7):1630-1639. Epub 2016 Nov 25.
Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun. 2017 Jul 28;8(1):153.
Göckeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenrück F, Neumann L, Hallek M, Krause G. Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 Sep;178(6):949-953. Epub 2017 Jun 1.
Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep;92(9):946-965.
Krause SW, Oldenburg M, Hallek M, Neubauer A. Prioritäten deutscher Onkologen. Auswertung der „Klug entscheiden“-Umfrage der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO). Dtsch Med Wochenschr. 2017 Sep;142(18):e124-e130. Epub 2017 Sep 8.
Lehmann C, Kochanek M, Abdulla D, Becker S, Böll B, Bunte A, Cadar D, Dormann A, Eickmann M, Emmerich P, Feldt T, Frank C, Fries J, Gabriel M, Goetsch U, Gottschalk R, Günther S, Hallek M, Häussinger D, Herzog C, Jensen B, Kolibay F, Krakau M, Langebartels G, Rieger T, Schaade L, Schmidt-Chanasit J, Schömig E, Schüttfort G, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M, Wieland U, Wiesmüller G, Wolf T, Fätkenheuer G. Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Euro Surveill. 2017 Sep;22(39).
Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy. Cancer Immunol Res. 2017 Sep;5(9):730-743. Epub 2017 Aug 4.
Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic lymphocytic leukemia with mutated IGHV4-34 receptors: shared and distinct immunogenetic features and clinical outcomes. Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. Epub 2017 May 23.
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 Oct;31(10):2251-2253. Epub 2017 Jul 12.
Eichhorst B, Hallek M. Erratum zu: Chronische lymphatische Leukämie. Therapiekonzepte im Wandel. Internist (Berl). 2017 Oct;58(10):1124.
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. Epub 2017 Sep 12.
Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, Kreuzer KA, Hallek M, Drexler HG, Chacko J, Wallis L, Fabarius A, Metzgeroth G, Hofmann WK, Chase A, Tapper W, Reiter A, Cross NCP. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia. 2017 Oct;31(10):2271-2273. Epub 2017 Jul 28.
Scheffold A, Jebaraj BMC, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br J Haematol. 2017 Oct;179(2):342-346. Epub 2016 Jul 8.
Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A, Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR. Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017 Oct;31(10):2244-2247. Epub 2017 Jun 27.
Gruell H, Hamacher L, Jennissen V, Tuchscherer A, Ostendorf N, Löffler T, Hallek M, Kochanek M, Tannich E, Böll B, Fätkenheuer G. On taking a different route: an unlikely case of malaria by nosocomial transmission. Clin Infect Dis. 2017 Oct 15;65(8):1404-1406.
Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L. Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 Nov;282(5):415-428. Epub 2017 Mar 14.
Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR. Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood. 2017 Nov 30;130(22):2443-2444. Epub 2017 Oct 19.
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 Dec;31(12):2833-2837. Epub 2017 Aug 14.
Fischer K, Hallek M. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):338-345. https://doi.org/10.1182/asheducation-2017.1.338

2018

Bokemeyer C, Hallek M, Lüftner D, Weissinger F. Vorwort. Oncol Res Treat. 2018;41(Suppl 3):1. Epub 2018 Jul 26.
Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B. Der ältere Krebspatient – Herausforderungen im Krankenhaus und in der Praxis. Oncol Res Treat. 2018;41(Suppl 3):2-26. Epub 2018 Jul 26.
Hahn M, Bürckert JP, Luttenberger CA, Klebow S, Hess M, Al-Maarri M, Vogt M, Reißig S, Hallek M, Wienecke-Baldacchino A, Buch T, Muller CP, Pallasch CP, Wunderlich FT, Waisman A, Hövelmeyer N. Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling. Leukemia. 2018 Jan;32(1):72-82. Epub 2017 Jun 1.
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. 2018 Jan 17.
Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U. Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2018 Jan 2;13(1):e0190802.
Streckmann F, Balke M, Lehmann HC, Rustler V, Koliamitra C, Elter T, Hallek M, Leitzmann M, Steinmetz T, Heinen P, Baumann FT, Bloch W. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies – STOP. BMC Cancer. 2018 Jan 10;18(1):62.
Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 Jan 15;142(2):322-333. Epub 2017 Oct 9.
Goede V, Hallek M. Welche hämato-onkologischen Medikamente sind im Alter entbehrlich oder ungeeignet? Dtsch Med Wochenschr. 2018 Feb;143(4):244-252. Epub 2018 Feb 22.
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A. Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 2018 Feb;32(2):364-375. Epub 2017 Aug 14.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018 Feb 15;9(1):697.
Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 Feb 20;9(1):727.
Baltin CT, Bludau M, Kron F, Zander T, Hallek M, Hölscher AH, Schröder W. Profit-Center-Analyse der Ösophagektomie. Ökonomische Analyse der transthorakalen Ösophagektomie in Abhängigkeit von postoperativen Komplikationen. Chirurg. 2018 Mar;89(3):229-236.
Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar;14(6):499-513. Epub 2018 Feb 21.
Kochanek M, Hallek M, Lehnert H, Schellong SM. Internistische Notfälle an der Schnittstelle von ambulant und stationär – Teil 2. Internist (Berl). 2018 Mar;59(3):217.
Kochanek M, Piepereit A, Böll B, Shimabukuro-Vornhagen A, Hallek M. Diagnostisches Management von Fieber. Internist (Berl). 2018 Mar;59(3):218-226.
van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2018 Mar;53(3):255-263. Epub 2017 Dec 18.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 Mar 1;131(9):955-962. Epub 2017 Dec 18.
Hassenrück F, Knödgen E, Göckeritz E, Midda SH, Vondey V, Neumann L, Herter S, Klein C, Hallek M, Krause G. Sensitive detection of the natural killer cell-mediated cytotoxicity of anti-CD20 antibodies and its impairment by B-cell receptor pathway inhibitors. Biomed Res Int. 2018 Mar 19;2018:1023490.
Bosch F, Hallek M. Venetoclax after idelalisib: relevant progress for CLL. Blood. 2018 Apr 12;131(15):1632-1633.
Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018 Apr 14;391(10129):1524-1537. Epub 2018 Feb 21.
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 Apr 16;11(1):55.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. Epub 2018 Mar 14.
Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, Newton RU, Galvao DA. Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 2018 Jul;170(1):1-13. Epub 2018 Feb 22.
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. Epub 2017 Oct 24.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. Epub 2018 May 1.
Strunk MA, Zopf EM, Steck J, Hamacher S, Hallek M, Baumann FT. Effects of kyusho jitsu on physical activity-levels and quality of life in breast cancer patients. In Vivo. 2018 Jul-Aug;32(4):819-824.
Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 2018 Aug 1;78(15):4270-4281. Epub 2018 May 18.
Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018 Aug 21;12:2577-2590.
Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 Sep;19(9):1215-1228. Epub 2018 Aug 13.
von Tresckow J, Hallek M, Eichhorst B. Individualisierte Therapie der chronischen lymphatischen Leukämie. Dtsch Med Wochenschr. 2018 Sep;143(18):1318-1324. Epub 2018 Sep 10.
Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. Epub 2018 Jun 12.
Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V. Does exercise have a preventive effect on secondary lymphedema in breast cancer patients following local treatment? – a systematic review. Breast Care (Basel). 2018 Oct;13(5):380-385. Epub 2018 May 3.
Golfmann K, Meder L, Koker M, Volz C, Borchmann S, Tharun L, Dietlein F, Malchers F, Florin A, Büttner R, Rosen N, Rodrik-Outmezguine V, Hallek M, Ullrich RT. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 Oct;37(42):5682-5693. Epub 2018 Jul 3.
Kochanek M, Böll B, Shimabukuro-Vornhagen A, Welte T, Wieland U, Pletz M, Hallek M, Fätkenheuer G, Salzberger B. Influenzasaison 2017/2018 – „business as usual“? Eine Stellungnahme der Fachgesellschaften. Internist (Berl). 2018 Oct;59(10):1122-1124.
Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 Oct 8;8(1):14941.
Hallek M. On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8.
Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 Dec;183(5):727-735. Epub 2018 Nov 21.
Eichhorst B, Hallek M, Goede V. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 Dec;58:7-13.

2019

Hallek M, Eichhorst B, Catovsky D, Eds. Chronic Lymphocytic Leukemia. Hematologic Malignancies. Cham, Switzerland: Springer; 2019.
Eichhorst B, Hallek M. Guidelines for diagnosis, indications for treatment, response assessment, and supportive management of chronic lymphocytic leukemia: the 2018 update. In Hallek M, Eichhorst B, Catovsky D, Eds. Chronic Lymphocytic Leukemia. Hematologic Malignancies. Cham, Switzerland: Springer; 2019: 69-77.
Eichhorst B, Al-Sawaf O, Hallek M. Initial therapy of chronic lymphocytic leukemia. In Hallek M, Eichhorst B, Catovsky D, Eds. Chronic Lymphocytic Leukemia. Hematologic Malignancies. Cham, Switzerland: Springer; 2019: 79-96.
Gärtner J, Daun M, Wolf J, von Bergwelt-Baildon M, Hallek M. Early palliative care: pro, but please be precise! Oncol Res Treat. 2019;42(1-2):11-18. Epub 2019 Jan 26.
Bühl L, Abel T, Wolf F, Oberste M, Bloch W, Hallek M, Elter T, Zimmer P. Feasibility and potential benefits of an exercise intervention in a male with down syndrome undergoing high-dose chemotherapy for acute lymphoblastic leukemia: a case report. Integr Cancer Ther. 2019 Jan;18:1534735419832358.
Hallek M, Haller H. Multiples Myelom. Internist (Berl). 2019 Jan;60(1):1-2.
Tresckow JV, Eichhorst B, Bahlo J, Hallek M. The treatment of chronic lymphatic leukemia. Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46.
Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood. 2019 Jan 31;133(5):494-497. Epub 2018 Nov 19.
Nguyen PH, Niesen E, Hallek M. New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019 Mar;33(3):576-587. Epub 2019 Jan 30.
Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 Mar;60(3):649-657. Epub 2018 Sep 20.
Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C. Allogeneic hematopoietic cell transplantation in patients aged 50 years or older with severe aplastic anemia. Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. Epub 2018 Sep 5.
Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group. Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. Br J Haematol. 2019 Mar;184(5):833-836. Epub 2018 Mar 12.
Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, Odenthal M, Adriouch S, Salvetti A, Büning H. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep. 2019 Mar 6;9(1):3631.
Drößler L, Lehmann C, Töpelt K, Nierhoff D, Vehreschild JJ, Rybniker J, Hallek M, Fischer J, Stormberg V, Fätkenheuer G, Wieland U, Jung N. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019 Apr;47(2):293-300. Epub 2019 Jan 28.
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019 Apr;33(4):969-980. Epub 2018 Oct 12.
Bachurski D, Schuldner M, Nguyen PH, Malz A, Reiners KS, Grenzi PC, Babatz F, Schauss AC, Hansen HP, Hallek M, Pogge von Strandmann E. Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracell Vesicles. 2019 Apr 1;8(1):1596016.
Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP. Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Haematologica. 2019 May;104(5):e224-e226. Epub 2019 Feb 21.
Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V, Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK, Eichhorst B, Hallek M. Small lymphocytic lymphoma: analysis of two cohorts including patients in clinical trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in “real-life” outside of clinical trials. Anticancer Res. 2019 May;39(5):2591-2598.
von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 May;33(5):1161-1172. Epub 2018 Dec 19.
Hallek M, Fürstenau M. How to approach CLL in clinical practice. Hematol Oncol. 2019 Jun;37(Suppl 1):38-42.
Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 Jun;60(6):1438-1446. Epub 2018 Nov 8.
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O’Brien SM, Stilgenbauer S. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. Epub 2019 Apr 17.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. Epub 2019 Jun 4.
Chmielewski M, Kuehle J, Chrobok D, Riet N, Hallek M, Abken H. FimH-based display of functional eukaryotic proteins on bacteria surfaces. Sci Rep. 2019 Jun 10;9(1):8410.
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 Jul 11;134(2):111-122. Epub 2019 Apr 25.
Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019 Jul 25;178(3):699-713.e19. Epub 2019 Jul 4.
Fürstenau M, De Silva N, Eichhorst B, Hallek M. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere. 2019 Aug 9;3(5):e287. eCollection 2019 Oct.
Schuldner M, Dörsam B, Shatnyeva O, Reiners KS, Kubarenko A, Hansen HP, Finkernagel F, Roth K, Theurich S, Nist A, Stiewe T, Paschen A, Knittel G, Reinhardt HC, Müller R, Hallek M, von Strandmann EP. Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. Theranostics. 2019 Aug 14;9(21):6047-6062.
Baltin C, Kron F, Urbanski A, Zander T, Kron A, Berlth F, Kleinert R, Hallek M, Hoelscher AH, Chon SH. The economic burden of endoscopic treatment for anastomotic leaks following oncological Ivor Lewis esophagectomy. PLoS One. 2019 Aug 28;14(8):e0221406.
Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am J Hematol. 2019 Sep;94(9):1002-1006. Epub 2019 Jul 8.
Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019 Sep;33(9):2183-2194. Epub 2019 Mar 25.
Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U. Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 Sep;104(9):1798-1803. Epub 2019 Feb 7.
Weiss J, Peifer M, Herling CD, Frenzel LP, Hallek M. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.). Haematologica. 2019 Nov;104(11):e540.
Fürstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019 Nov;104(11):2144-2154. Epub 2019 Oct 4.
Eichenauer DA, Golla H, Thielen I, Hallek M, Voltz R, Perrar KM. Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Ann Hematol. 2019 Nov;98(11):2605-2607. Epub 2019 Jun 28.
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019 Nov;94(11):1266-1287. Epub 2019 Oct 4.
Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol. 2019 Nov;20(11):1576-1586. Epub 2019 Sep 30.
Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O’Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. Epub 2019 Jul 15.
Eichhorst B, Fürstenau M, Hallek M. Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):482-489.
Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2019 Dec 26. [Epub ahead of print]

2020

Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O’Brien SM, Pettitt AR, Hallek M. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximabLeukemia. 2020 Jan;34(1):296-300. Epub 2019 Aug 19.
Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR, Larsen J, Niemann CU.Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun. 2020 Jan 17;11(1):363.
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). Hemasphere. 2020 Jan 27;4(1):e336.
Fürstenau M, Simon F, Cornely OA, Hicketier T, Eichhorst B, Hallek M, Mellinghoff SC. Invasive Aspergillosis in Patients Treated With Ibrutinib. Hemasphere. 2020 Feb 13;4(2):e309. eCollection 2020 Apr.
Al-Sawaf O, Eichhorst B, Hallek M. Chronische lymphatische Leukämie. Internist (Berl). 2020 Mar;61(3):277-287.
Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia Leukemia. 2020 Mar;34(3):924-928. Epub 2019 Oct 14.
Jenniches I, Lemmen C, Cwik JC, Kusch M, Labouvie H, Scholten N, Gerlach A, Stock S, Samel C, Hagemeier A, Hellmich M, Haas P, Hallek M, Pfaff H, Dresen A. Evaluation of a complex integrated, cross-sectoral psycho-oncological care program (isPO): a mixed-methods study protocolBMJ Open. 2020 Mar 9;10(3):e034141.
Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, Tandon M, Jiang Y, Schary W, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer KA. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.Blood. 2020 Mar 12;135(11):866-870.
Knuever J, Weiss J, Persa OD, Kreuzer K, Mauch C, Hallek M, Schlaak M. The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci Rep. 2020 Mar 18;10(1):4940.
Hansen HP, Paes Leme AF, Hallek M. Role of ADAM10 as a CD30 sheddase in classical Hodgkin lymphomaFront Immunol. 2020 Mar 31;11:398. eCollection 2020.
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U, Jacobs G, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S, Hallek M. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupLeukemia. 2020 Apr;34(4):1038-1051. Epub 2020 Feb 10.
Fürstenau M, Hopfinger G, Robrecht S, Fink AM, Al-Sawaf O, Langerbeins P, Cramer P, Tresckow JV, Maurer C, Kutsch N, Hoechstetter M, Dreyling M, Lange E, Kneba M, Stilgenbauer S, Döhner H, Hensel M, Kiehl MG, Jaeger U, Wendtner CM, Goede V, Fischer K, von Bergwelt-Baildon M, Eichhorst B, Hallek M, Theurich S. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapyLeukemia. 2020 Apr;34(4):1177-1181. Epub 2019 Nov 14.
Rothe A, Claßen A, Carney J, Hallek M, Mellinghoff SC, Scheid C, Holtick U, von Bergwelt-Baildon M. Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysisEur J Haematol. 2020 Apr;104(4):291-298. Epub 2020 Jan 20.
Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, Dietlein F, Borchmann S, Chatterjee S, Siobal M, Schöttle J, Florin A, Koker M, Nill M, Ozretić L, Uhlenbrock N, Smith S, Büttner R, Miao H, Wang B, Reinhardt HC, Rauh D, Hallek M, Acker-Palmer A, Heukamp LC, Ullrich RT. Inhibition of tumor VEGFR2 induces serine 897 EphA2-dependent tumor cell invasion and metastasis in NSCLCCell Rep. 2020 Apr 28;31(4):107568.
Augustin M, Schommers P, Suárez I, Koehler P, Gruell H, Klein F, Maurer C, Langerbeins P, Priesner V, Schmidt-Hellerau K, Malin JJ, Stecher M, Jung N, Wiesmüller G, Meissner A, Zweigner J, Langebartels G, Kolibay F, Suárez V, Burst V, Valentin P, Schedler D, Cornely OA, Hallek M, Fätkenheuer G, Rybniker J, Lehmann C. Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020Euro Surveill. 2020 May;25(21):2000531.
Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA, Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V, Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S. Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcriptionHaematologica. 2020 May;105(5):1379-1390. Epub 2019 Aug 29.
Krause G, Hassenrück F, Hallek M. Cell line-based assessment of BTK inhibitors. Br J Pharmacol. 2020 May;177(9):2163-2165. Epub 2020 Jan 28.
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, Hallek M, Jung N, Klein F, Persigehl T, Rybniker J, Kochanek M, Böll B, Shimabukuro-Vornhagen A. COVID-19 associated pulmonary aspergillosisMycoses. 2020 Jun;63(6):528-534. Epub 2020 May 15.
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21;135(21):1859-1869.
Augustin M, Hallek M, Nitschmann S. Remdesivir bei Patienten mit schwerer COVID-19. Internist (Berl). 2020 Jun;61(6):644-645.
Augustin M, Hallek M. Aktuelles Studienergebnis unterstreicht zurückhaltende Kommentierung. Internist (Berl). 2020 Jun;61(6):646.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Porro Lurà M, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S.Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxBlood. 2020 Jun 25;135(26):2402-2412.
Hallek M. Nichtzelluläre Immuntherapie in der Onkologie. Internist (Berl). 2020 Jul;61(7):651.
Koch M, Reinartz S, Saggau J, Knittel G, Rosen N, Fedorchenko O, Thelen L, Barthel R, Reinart N, Seeger-Nukpezah T, Reinhardt HC, Hallek M, Nguyen PH. Meta-analysis reveals significant sex differences in chronic lymphocytic leukemia progression in the Eµ-TCL1 transgenic mouse modelCancers (Basel). 2020 Jul 20;12(7):E1980.
Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E, Ghia P. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemicHemasphere. 2020 Jul 30;4(4):e432.
Augustin M, Hallek M, Nitschmann S. Remdesivir bei Patienten mit COVID-19. Internist (Berl). 2020 Aug;61(8):869-872.
Cramer P, von Tresckow J, Eichhorst B, Hallek M.Aktuelle Standards in der Diagnostik und Therapie der chronischen lymphatischen Leukämie. Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. Epub 2020 Aug 13.
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V.Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialLeukemia. 2020 Aug;34(8):2038-2050. Epub 2020 Feb 18.
Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, van der Klift M, van der Spek E, Illmer T, Schöttker B, Fischer K, Wendtner CM, Tausch E, Stilgenbauer S, Niemann CU, Gregor M, Kater AP, Hallek M, Eichhorst B.COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 Aug;34(8):2225-2229. Epub 2020 Jun 29.https://doi.org/10.1038/s41375-020-0941-7
Barbarino V, Henschke S, Blakemore SJ, Izquierdo E, Michalik M, Nickel N, Möllenkotte I, Vorholt D, Müller L, Brinker R, Fedorchenko O, Mikhael N, Seeger-Nukpezah T, Hallek M, Pallasch CP. Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by ibrutinib via inhibition of JAK2Cancers (Basel). 2020 Aug 15;12(8):2303.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialLancet Oncol. 2020 Sep;21(9):1188-1200.
Krause G, Hassenrück F, Hallek M. Relevant cytokines in the B cell lymphoma micro-environment. Cancers (Basel). 2020 Sep 5;12(9):E2525.
Di Cristanziano V, Meyer-Schwickerath C, Eberhardt KA, Rybniker J, Heger E, Knops E, Hallek M, Klein F, Holtick U, Jung N. Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 2020 Sep 18. [Epub ahead of print]
Jakobs F, Drost RMWA, Kron A, Heinen J, Hallek M, Reinhardt HC, Zander T, Kron F.Economic Impact of the Introduction of Outpatient Medical Specialist Care (ASV) of Gastrointestinal Cancer Patients from a German Hospital Management PerspectiveOncol Res Treat. 2020;43(10):498-505. Epub 2020 Sep 21.
Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, von Jan J, Chmielewski M, Ianevski A, Diebner HH, Mayer P, Kondo Ados A, Wahnschaffe L, Braun T, Müller TA, Wagle P, Bouska A, Neumann T, Pützer S, Varghese L, Pflug N, Thelen M, Makalowski J, Riet N, Göx HJM, Rappl G, Altmüller J, Kotrova M, Persigehl T, Hopfinger G, Hansmann ML, Schlößer H, Stilgenbauer S, Dürig J, Mougiakakos D, von Bergwelt-Baildon M, Roeder I, Hartmann S, Hallek M, Moriggl RH, Brüggemann M, Aittokallio T, Iqbal J, Newrzela S, Abken H, Herling M.Non-canonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signalingBlood. 2020 Sep 21:blood.2019003348. [Epub ahead of print]
Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis ZA, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper R, Sutton LA, Baliakas P, Scarfò L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville A, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Stranska K, Ritgen M, Facco M, Tresoldi C, Visentin A, Patriarca A, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Skuhrova Francova H, Moysiadis T, Veronese SM, Giannopoulos K, Mansouri L, Karan-Djurasevic T, Sandaltzopoulos R, Bödör C, Fais F, Kater AP, Panovska-Stavridis I, Rossi D, Alshemmari S, Panagiotidis P, Costeas PA, Espinet B, Antic D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, Francia di Celle P, Niemann CU, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier DG, Stilgenbauer S, Haferlach C, Jelinek DF, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.Higher-order connections between stereotyped subsets: implications for improved patient classification in CLLBlood. 2020 Sep 29:blood.2020007039. [Epub ahead of print]
Tzaridis T, Reiners KS, Weller J, Bachurski D, Schäfer N, Schaub C, Hallek M, Scheffler B, Glas M, Herrlinger U, Wild S, Coch C, Hartmann G.Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic SignatureInt J Mol Sci. 2020 Sep 29;21(19):E7211.
Braun F, Rinschen M, Buchner D, Bohl K, Plagmann I, Bachurski D, Richard Späth M, Antczak P, Göbel H, Klein C, Lackmann JW, Kretz O, Puelles VG, Wahba R, Hallek M, Schermer B, Benzing T, Huber TB, Beyer A, Stippel D, Kurschat CE, Müller RU.The proteomic landscape of small urinary extracellular vesicles during kidney transplantation. J Extracell Vesicles. 2020 Oct;10(1):e12026. Epub 2020 Nov 19.
Ghia P, Coutre SE, Cheson BD, Barrientos JC, Hillmen P, Pettitt AR, Zelenetz AD, Shreay S, Hallek M, Furman RR. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trialHaematologica. 2020 Oct;105(10):e519-e522. Epub 2020 Feb 13.
Langerbeins P, Fürstenau M, Gruell H, Klein F, Persigehl T, Rybniker J, Seeger-Nukpezah T, Kochanek M, Hallek M, Eichhorst B, Koehler P, Böll B.COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. Eur J Haematol. 2020 Oct;105(4):508-511. Epub 2020 Jul 10.
Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, Altmüller J, Illerhaus G, Ruge MI, Maarouf M, Büttner R, Hansmann ML, Hallek M, Prinz M, Siebert R, Deckert M. Analysis of driver mutational hot spots in blood-derived cell-free DNA of patients with primary central nervous system lymphoma obtained before intracerebral biopsyJ Mol Diagn. 2020 Oct;22(10):1300-1307. Epub 2020 Aug 1.
Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; Committee for Clinical Cardiovascular Medicine of the German Cardiac Society. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical OncologyClin Res Cardiol. 2020 Oct;109(10):1197-1222. Epub 2020 May 13.
Stilgenbauer S, Morschhauser F, Wendtner CM, Cartron G, Hallek M, Eichhorst B, Kozloff MF, Giever T, Lozanski G, Jiang Y, Huang H, Pignataro DS, Schary W, Humphrey K, Mobasher M, Salles G. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Haematologica. 2020 Oct 29. [Epub ahead of print]
Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hoevelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling CD, Hartmann E, Rosenwald A, Klapper W, Buettner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt HC, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT. –Active AKT signaling triggers CLL towards Richter’s transformation via over-activation of Notch1. Blood. 2020 Nov 2:blood.2020005734. [Epub ahead of print]
Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Haematologica. 2020 Nov 1;105(11):2598-2607
Augustin M, Hallek M, Nitschmann S. Morphologische und molekulare Veränderungen der Lungen von Patienten mit COVID-19. Internist (Berl). 2020 Dec;61(12):1304-1307.
Barthel R, Fedorchenko O, Velmans T, Rosen N, Nguyen PH, Reinart N, Florin A, Herling M, Hallek M, Fingerle-Rowson G. CD74 is dispensable for development of chronic lymphocytic leukemia in Eµ-TCL1 transgenic miceLeuk Lymphoma. 2020 Dec;61(12):2799-2810. Epub 2020 Jul 15. https://doi.org/10.1080/10428194.2020.1791851
Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaLeuk Lymphoma. 2020 Dec;61(13):3188-3197. Epub 2020 Aug 6.
Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemiaHematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-362.
Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, von Jan J, Chmielewski M, Ianevski A, Diebner HH, Mayer P, Kondo Ados A, Wahnschaffe L, Braun T, Müller TA, Wagle P, Bouska A, Neumann T, Pützer S, Varghese L, Pflug N, Thelen M, Makalowski J, Riet N, Göx HJM, Rappl G, Altmüller J, Kotrová M, Persigehl T, Hopfinger G, Hansmann ML, Schlößer H, Stilgenbauer S, Dürig J, Mougiakakos D, von Bergwelt-Baildon M, Roeder I, Hartmann S, Hallek M, Moriggl R, Brüggemann M, Aittokallio T, Iqbal J, Newrzela S, Abken H, Herling M. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signalingBlood. 2020 Dec 10;136(24):2786-2802.
Kohlhas V, Hallek M, Nguyen PH. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 miceBlood Adv. 2020 Dec 22;4(24):6106-6116.

2021

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M, Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst B. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021 Jan;35(1):169-176. Epub 2020 Mar 17.
Augustin M, Hallek M, Nitschmann S. Impfstoffentwicklung zur Prävention von COVID-19. Internist (Berl). 2021 Jan;62(1):106-110. Epub 2020 Dec 23.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23-33. Epub 2020 Oct 19.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):223-234. https://doi.org/10.1016/S1470-2045(20)30601-X
Cramer P, V Tresckow J, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N, Al-Sawaf O, Heinz WJ, Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trialHaematologica. 2021 Feb 1;106(2):543-554. Epub 2020 Feb 27.
Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hövelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling C, Hartmann EM, Rosenwald A, Klapper W, Büttner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt HC, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021 Feb 4;137(5):646-660.
Augustin M, Hallek M, Nitschmann S. Impfstoffentwicklung zur Prävention von COVID-19 – Teil 2. Internist (Berl). 2021 Mar;62(3):337-340. Epub 2021 Feb 9.
Beckmann L, Berg V, Dickhut C, Sun C, Merkel O, Bloehdorn J, Robrecht S, Seifert M, da Palma Guerreiro A, Claasen J, Loroch S, Oliverio M, Underbayev C, Vaughn LT, Thomalla D, Huelsemann MF, Tausch E, Fischer K, Fink AM, Eichhorst B, Sickmann A, Wendtner CM, Stilgenbauer S, Hallek M, Wiestner A, Zahedi RP, Frenzel LP. MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood. 2021 Mar 18:blood.2020009165. [Epub ahead of print]
Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S. Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patientsHaematologica. 2021 Mar 18. [Epub ahead of print]
Zimmer P, Hillebrand P, Wolf F, Joisten N, Walzik D, Hardt L, Großek A, Hartig P, Kierdorf F, Belz M, Tinschmann M, Kiesl D, Bloch W, Groß-Ophoff-Müller C, Hallek M, Böll B, Oberste M, Elter T. Impact of induction chemotherapy on objective and self-perceived cognitive performance in patients suffering from hematological disordersLeuk Lymphoma. 2021 Apr 21:1-5. [Epub ahead of print].
Kron F, Franz J, Kron A, Hallek M. Ökonomie und Management bei der CAR-T-Zell-Therapie : Status quo und Ausblick [Economics and management of CAR T- cell therapy : Status quo and future perspectives]Internist (Berl). 2021 May 4. German. [Epub ahead of print].
Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, Fink AM, Fischer K, Zhang C, Betel D, Gnirke A, Imielinski M, Moreaux J, Hallek M, Meissner A, Stilgenbauer S, Wu CJ, Elemento O, Landau DA. Discovery of candidate DNA methylation cancer driver genes. Cancer Discov. 2021 May 10:candisc.1334.2020. [Epub ahead of print].
Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B, Hallek M, Fischer K. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trialAm J Hematol. 2021 May 29. [Epub ahead of print].
Simon ST, Pralong A, Hallek M, Scheid C, Holtick U, Herling M. What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)? Ann Hematol. 2021 Jun;100(6):1377-1389. [Epub 2021 May 6].
Augustin M, Hallek M, Nitschmann S. Impfstoffentwicklung zur Prävention von COVID-19 – Teil 3 [Development of vaccines for prevention of COVID-19: part 3]. Internist (Berl). 2021 Jun;62(6):690-693. German. [Epub 2021 May 27].
Hallek M. Zelluläre Immuntherapien [Cellular immunotherapies]. Internist (Berl). 2021 Jun;62(6):581-582. German. Epub 2021 Jun 9.
Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O, Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M. Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/or MutationsBlood. 2021 Jun 4:blood.2020010484. [Epub ahead of print]
Theobald SJ, Simonis A, Georgomanolis T, Kreer C, Zehner M, Eisfeld HS, Albert MC, Chhen J, Motameny S, Erger F, Fischer J, Malin JJ, Gräb J, Winter S, Pouikli A, David F, Böll B, Koehler P, Vanshylla K, Gruell H, Suárez I, Hallek M, Fätkenheuer G, Jung N, Cornely OA, Lehmann C, Tessarz P, Altmüller J, Nürnberg P, Kashkar H, Klein F, Koch M, Rybniker J. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19EMBO Mol Med. 2021 Jun 16:e14150. [Epub ahead of print].
Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, Hallek M, Fuhr U, Vehreschild JJ, Jakob C. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer. 2021 Jun 20;21(1):719.
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, Roventa M, Riaz T, Tschernoster N, Altmueller J, Rose L, Salomon S, Priesner V, Luers JC, Albus C, Rosenkranz S, Gathof B, Fätkenheuer G, Hallek M, Klein F, Suárez I, Lehmann C. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122. [Epub 2021 May 18].
Castelli L, Elter T, Wolf F, Watson M, Schenk A, Steindorf K, Bloch W, Hallek M, Joisten N, Zimmer P. Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapySupport Care Cancer. 2021 Jul 10. [Epub ahead of print].